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 For a dying person, a transplant is not a difficult 
decision. If a lion chases you to a river filled with 
crocodiles, you will leap into the water convinced you 
have a chance to swim to the other side. But you 
would never accept such odds if there were no lion… 
Dr. Christiaan Barnard
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ABSTRACT 
For patients with end-stage heart failure, heart transplantation remains the only viable 
long-term option. During the last fifty years, the procedure has become more successful, 
and the majority of candidates can now expect to recover and lead relatively normal 
day-to-day lives. Unfortunately, however, it is not a perfect cure. Daily lifelong 
immunosuppression is required to protect against rejection, and current drug regimens 
have substantial side-effects including infection, renal failure and hypertension, all of 
which further shorten life expectancy. Current post-transplant graft survival is estimated 
at 15 to 20 years, after which re-transplantation is indicated; with donation rates 
decreasing, and potential recipient numbers increasing, this is by no means certain.  
 
This thesis represents a body of work aiming to show improving outcomes for children 
at different stages of the transplant journey. Pre-transplant diagnosis has long been 
thought a predictor of outcome, with worse results for patients transplanted for 
congenital heart disease than cardiomyopathy. This work showed that with increasing 
specific surgical expertise, this bias has now largely disappeared. Restrictive 
cardiomyopathy, pre-transplant extra-corporeal membranous oxygenation and extreme 
donor:recipient weight ratio were all shown to increase the need for extra-corporeal life 
support as a rescue therapy in the immediate post-operative phase; this  was associated 
with excellent medium-term survival in patients surviving to hospital discharge. Pre-
implantation use of the induction immunosuppression basiliximab was evaluated, 
indicating a reduction in acute rejection and mortality in the first 6 months post-
transplant. Maintenance immunotherapy was also investigated, suggesting an improved 
side-effect profile seen in children taking tacrolimus rather than ciclosporin. Finally, 
cytomegalovirus was linked to the most important cause of death for patients over five 
years post-transplant – namely coronary allograft vasculopathy – as well as 
morphological and functional impairment in the systemic vasculature of heart transplant 
Abstract 
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recipients. In summary, this thesis indicates an improving outcome for children at every 
stage of the post-transplant journey. 
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1.1 INTRODUCTION 
Heart transplantation is a potentially life-saving procedure reserved for a very limited 
number of patients who suffer with end-stage, intractable heart failure. It is a rare 
treatment, performed in relatively few, super-specialised hospitals throughout the world. 
Paediatric heart transplantation is rarer still, which currently occurs in only two centres 
in the UK: the Freeman Hospital in Newcastle, and Great Ormond Street Hospital for 
Children in London. 
 
The operation was first performed in a human subject by Christiaan Barnard in 1967. 
His early work, along with many other of the pioneers of heart transplantation, remains 
the basis for today‘s transplant units, although every area of the discipline has 
undergone continuous evolution – and occasional revolution – throughout the last fifty 
years.  
 
An effective transplantation is dependent on much more than the operation alone. 
Rather, it relies on a combination of processes, all of which must be optimised to ensure 
the best chance of graft survival. Pre-transplant factors, both in the recipient (e.g. 
pulmonary hypertension) and the donor (e.g. ischaemia around the time of death), may 
preclude a successful outcome, regardless of the best attempts of surgeons, intensivists 
and physicians to maintain or revive graft function. And each of these areas – surgical 
technique, intensive care strategies, and post-transplant care – must also be delivered at 
the highest standard, if a transplant programme is to prosper. 
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To ensure constant improvement in our services, we must not forget the courage and 
drive for innovation that those early pioneers possessed, which allowed what was 
considered science fiction in the first part of the 20
th
 Century to become the reality that 
transplant is today. Research must be at the very core of every unit‘s philosophy: 
reflecting on one‘s own practices, learning from other programmes, and developing 
novel strategies to prevent, reverse or reduce the potential mortality and morbidity that 
remains at every step of the transplant process. Great Ormond Street Hospital has 
always been at the forefront of such innovation, and I hope that – through this thesis – I 
have been able to advance our knowledge and understanding of paediatric heart 
transplantation. 
 
1.2 AIMS AND OBJECTIVES 
This work aims to demonstrate improving overall outcomes for children undergoing 
heart transplantation by careful analysis of several of the components of the transplant 
journey, namely: the impact of the original diagnosis of the patient on the success of 
transplantation; immediate post-operative intensive care management; 
immunosuppression (both induction and maintenance therapy) and the side-effects of 
treatment; and infections and their role in vascular health (peripheral and coronary). My 
thesis therefore combines the following objectives: 
1. To compare outcomes of paediatric heart transplantation depending on 
indication (cardiomyopathy versus congenital heart disease) 
2. To quantify the success and understand the risk factors associated with the need 
for extra-corporeal life support in the immediate post-operative setting 
3. To understand the impact of recent changes in post-transplant medications with 
regards to their common side-effect profile 
4. To examine the benefits of a specific induction therapy (basiliximab) in 
paediatric heart transplantation 
5. To study the effect of cytomegalovirus on the peripheral and coronary 
vasculature in the post-transplant setting 
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1.3 THESIS OUTLINE 
The thesis consists of an overview of paediatric heart failure and heart 
transplantation, followed by original research designed to answer the questions posed 
by the aims and objectives cited above. Specifically: 
Chapter 2 outlines the physiology of paediatric heart failure, and describes current 
modalities of treatment (both pharmacological and mechanical). It then goes on to 
describe an overview of paediatric heart transplantation, outlining a brief history, 
clinical indications and timing of transplant, mechanical support as a bridge to 
transplantation, surgical procedure, immunosuppression, and common post-
transplant morbidities (such as renal disease, lymphoma and cardiac allograft 
vasculopathy). 
Chapter 3 compares the overall outcome in children transplanted for 
cardiomyopathies against those transplanted for congenital heart disease, and further 
investigates post-transplant survival for different congenital heart disease diagnoses. 
Chapter 4 reviews the use of extra-corporeal life support as an emergency life-saving 
measure in the immediate post-transplant phase, indicating its relatively high 
incidence, highlighting certain risk factors for its requirement (e.g. restrictive 
cardiomyopathy), and – despite its high early morbidity – an excellent outlook for 
those who survive to hospital discharge. 
Chapter 5 examines the results of the evolution of induction immunosuppression, 
from the early use of the broad spectrum anti-thymocyte globulin, to the more 
targeted CD25 monoclonal antibody basiliximab, demonstrating a reduction in both 
acute rejection and post-transplant lymphoproliferative disease. 
Chapter 6 explores the impact of post-transplant drug therapy with regards to 
associated morbidities (such as renal impairment, diabetes, hyperlipidaemia and 
hypertension). 
Chapters 7 and 8 investigate the vascular effects of cytomegalovirus (CMV) in the 
post-transplant setting. Chapter 7 reveals a reduction in peripheral vascular health 
associated with post-transplant CMV replication, and Chapter 8 indicates the 
accelerated morphological changes within the coronary arteries of transplant patients 
with CMV. 
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Chapter 9 summarises the results of this thesis, describing the effect of the 
improvements seen in surgical, medical and intensive care of paediatric heart 
transplant patients, and highlights on-going challenges and potential future directions 
in the field. 
 
 CHAPTER 2 
PAEDIATRIC HEART FAILURE AND               
HEART TRANSPLANTATION 
 
 
Paediatric heart failure is a relatively uncommon presentation, but one which has 
potentially devastating results. The most severe cases will require intensive care, with 
ventilatory, circulatory and perhaps mechanical support; it is these children who may 
go on to require and receive a heart transplant. It is of vital importance, therefore, to 
understand the pathological basis of heart failure, in order to implement and develop 
treatment strategies that improve outcomes in these patients, both in terms of quality of 
life, and overall (transplant-free) survival. And in order to understand heart failure, an 
in-depth understanding of normal cardiac physiology is required. 
 
Most of what we know of heart function and failure is derived from adult studies. 
Although this information is fundamental to how we think about paediatric cardiology, 
it is essential to bear in mind that “children are not small adults”, and extrapolations 
from adult practice must be translated into the paediatric sphere only with a thorough 
grounding in the differences between the study population and the patient.  
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The first part of this chapter presents an overview of each of these matters. It begins 
with the basic physiology of myocardial contraction, and considers recent advances in 
our knowledge of cardiac function. This then serves as a basis on which to discuss the 
pathophysiology of heart failure, including intrinsic cardiac aspects, and extrinsic non-
cardiac features, including neurohormonal and immunological adaptations that are 
originally compensatory, but end up compounding the severity of the myocardial 
dysfunction. I discuss the subtle differences between children and adults, and then 
review current treatment for heart failure in children, and possible future advances in 
the field. 
 
The only long-term option for children with end-stage heart failure is heart 
transplantation. The second part of this chapter reviews the current state of play in the 
discipline. Features of those patients requiring transplantation are discussed, including 
indications for and timing of transplantation, and the subtle but important differences in 
paediatric compared to adult transplant. Specific issues concerning pre-transplant 
status are also mentioned, with particular reference to transplantation for congenital 
heart disease and the use of extra-corporeal life support post-transplant – two of the 
important areas that are investigated later in this thesis. Post-transplant problems – 
including immunosuppression and cardiac allograft vasculopathy – are then examined, 
before reviewing the overall survival figures published by The International Society for 
Heart and Lung Transplantation. 
 
 
  
Chapter 2  Paediatric heart failure & transplantation 
 8 
2.1 INTRODUCTION – PAEDIATRIC HEART FAILURE 
Worldwide, heart failure places a substantial burden on healthcare systems. The 
majority of adult cases are secondary to ischaemic heart disease and myocardial 
infarction. Whilst ischaemic heart disease is uncommon in children, heart failure is a 
significant problem. Most cases in the paediatric age group are due to congenital heart 
disease and cardiomyopathies, but other causes, (e.g. rhythm disturbances) or non-
cardiac causes (e.g. sepsis) are recognised. Over recent years, knowledge of the 
pathophysiology of heart failure has increased, which has led to improvements in the 
treatment of this disease. Most importantly, it is now possible to target therapies not 
only at improving myocardial function directly, but which aim to counteract other 
physiological changes that prove deleterious in the long term. The majority of this work 
has – inevitably – been derived from adult studies; nonetheless, with careful 
consideration in certain circumstances, this knowledge can be transferred to paediatric 
patients. However, in order to understand the pathophysiology of the failing heart, it is 
first essential to understand the physiology of the working heart. 
2.2 PHYSIOLOGY OF MYOCARDIAL CONTRACTION 
Cardiac muscle is composed of a latticework of muscle fibres, each composed of 
myofibrils made up of actin and myosin filaments. The actin and myosin filaments 
interdigitate, and are linked by small projections from the sides of the myosin filaments 
known as ‗cross-bridges‘; together, these filaments compose the functional unit of 
cardiac muscle – the sarcomere. The interaction of these cross-bridges generates 
mechanical forces that cause muscle contraction by the sliding filament mechanism.  
 
The myosin filament is comprised of 200 or more myosin molecules which are arranged 
into three portions.
1
 The body of the myosin molecules are collected together to form 
the central portion of the filament. The arm protrudes from the central body and, 
together with the head, forms the cross-bridge which interacts with the actin filament.  
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The actin filament also has three components. The backbone of the filament is two 
helical strands of F-actin, on which are situated many active sites (actually each a 
molecule of ADP) that interact with the myosin cross-bridges to cause contraction. In 
the resting state, however, these active sites are hidden by the second element of the 
actin filament, tropomyosin, which is a protein that wraps around the F-actin helix. The 
final portion of the actin filament is the protein troponin, itself comprised of three 
subunits (T, I and C), each of which plays a specific role in controlling muscle 
contraction. Troponin T binds troponin to tropomyosin, anchoring the protein to the 
filament. Troponin I has a strong affinity for actin and inhibits the interaction of actin 
and myosin, thus preventing contraction. When troponin C binds to calcium, a 
conformational change occurs in the troponin complex, uncovering the active sites of 
the actin, allowing them to interact with the myosin cross-bridges, and contraction 
follows (Figure 2.1). 
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Figure 2.1 Structure and function of myosin/actin complex. Without calcium (top), the I-subunit of 
troponin covers the myosin binding site, inhibiting contraction. As calcium binds to the C-subunit of 
troponin (bottom), the I-subunit is pulled away, permitting binding of the myosin head to the actin 
filament. This is followed by a conformational change in myosin, which pulls the actin filament from 
right to left. I, I-subunit of troponin; C, C-subunit of troponin; T, T-subunit of troponin; M, myosin-
binding site. Figure produced by Great Ormond Street Hospital Medical Illustration Department. 
 
Initiation of contraction begins with the cardiac action potential.
2
 As the action potential 
passes over the cardiac muscle membrane, it spreads to the interior of the muscle fibre 
along the membranes of the transverse tubules. These cause instantaneous release of 
calcium ions from the sarcoplasmic reticulum (SR) into the muscle sarcoplasm; these 
ions then diffuse into the myofibrils, causing the conformational change in the troponin 
complex leading to muscle contraction. During repolarization of the cardiac muscle, the 
calcium in the sarcoplasm is rapidly pumped back into the SR, causing relaxation of the 
muscle fibre and completing the cardiac cycle.  
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2.3 REGULATION OF CARDIAC OUTPUT 
Cardiac output (CO) can be defined as the product of stroke volume (SV) and heart rate 
(HR): 
 
CO = SV x HR 
 
Stroke volume is the amount of blood ejected from the ventricle in each cardiac cycle, 
or, in other terms, the difference between the end-diastolic volume (EDV) and the end-
systolic volume (ESV). EDV is dictated by preload, myocardial compliance and active 
relaxation, and ESV is a function of contractility and afterload. As stated by Frank, 
when the preload increases, the left ventricle distends, the left ventricular pressure 
development becomes more rapid and rises to a higher peak pressure, and the stroke 
volume augments.
3
 This increase in stroke volume, with a concomitant increase in heart 
rate, results in an increase in cardiac output (originally described by Starling).
4
 This 
relationship between venous return and cardiac output (the Frank–Starling relationship) 
is demonstrated by the increase in cardiac output during exercise or following the 
administration of intravenous fluid.  
 
The physiological basis on which the Frank–Starling law operates has two components.5 
Firstly, as in skeletal muscle, an increase in sarcomere length due to ventricular stretch 
optimizes the overlap of actin and myosin, forming more cross-bridges and increasing 
the force of contraction (although in contrast to skeletal muscle, cardiac muscle operates 
much closer to its optimal sarcomere length at all times; hence this effect is not as 
marked as in skeletal muscle). Secondly, an increased sarcomere length sensitizes 
troponin C to the prevailing calcium transient, leading to a steep increase in force as 
sarcomere length increases, i.e. length-dependent activation.
6
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An increase in cardiac output is also effected by an increase in afterload. This is 
described by the Anrep effect, i.e. an abrupt increase in aortic pressure is followed by a 
positive inotropic effect within 1–2 minutes.7 One postulated explanation of the Anrep 
effect is that increased left ventricular wall tension acts on myocardial stretch receptors 
to increase cytosolic calcium, independently of sarcomere length; it is also believed that 
stretch results in an increase in myofilament calcium responsiveness.
8
 Clinically, this 
increase in cardiac output may be seen in acute rises in blood pressure.  
 
An increase in heart rate will obviously lead directly to an increase in cardiac output 
(since CO = SV x HR). However, an increase in heart rate also leads to an increase in 
stroke volume by a process known as the treppe phenomenon (or Bowditch effect);
9
 
during rapid stimulation, more sodium and calcium ions enter the myocardial cell than 
can be removed, leading to a stepwise increase in available calcium, increasing the force 
of contraction. This is also known as the force–frequency relationship.  
2.4 PATHOPHYSIOLOGY OF HEART FAILURE 
Cardiac failure is the inability of the heart to deliver oxygen to the tissues at a rate 
commensurate with the metabolic demands. Broadly, it can be divided into systolic and 
diastolic failure, although the two are closely interlinked and often occur together in the 
same patient, particularly in advanced failure once adaptive mechanisms start to fail. 
The most common causes in the paediatric age group are congenital heart disease, 
cardiomyopathies and myocardial dysfunction following cardiac surgery,
10
 as well as 
rhythm disturbances and non-cardiac causes (e.g. bacterial sepsis).  
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2.4.1 Haemodynamic aspects of heart failure 
Cardiac failure can be seen as an inadequacy of the aforementioned homeostatic 
mechanisms to fully respond to the demand for cardiac output. Each homeostatic 
mechanism has an upper threshold, beyond which cardiac performance falls. For 
instance, as heart rate increases (increasing cardiac output), diastolic time (i.e. filling 
time) decreases. Decreasing filling time will, eventually, decrease the amount of blood 
in the ventricles at the end of diastole (i.e. EDV), and stroke volume will be reduced. 
When the decrease in stroke volume is proportionally greater than the increase in heart 
rate, the product of the two will decrease, i.e. cardiac output will start to fall. This 
situation of a pathologically high heart rate can be seen in many rhythmic disturbances, 
e.g. supraventricular tachycardia.  
 
Similarly, in the case of the Frank–Starling law of the heart, there is a point at which 
further increases in EDV are not met with an increased force of contraction, but rather 
stroke volume starts to tail off (Figure 2.2). This situation is thought of simply as 
volume overload. This condition arises in congenital left-to-right shunting lesions, such 
as a large patent ductus arteriosus or ventricular septal defect. As stroke volume falls, 
the volume overload itself gets worse, generating a vicious circle. In the case of 
afterload, there will come a point where further increases in arterial pressure cannot be 
matched with further increases in inotropy, and therefore the contractility of the heart 
will be insufficient to overcome the afterload. Again, stroke volume will decrease. 
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Figure 2.2 The Frank-Starling Curve. As preload increases, stroke volume increases in accordance 
with the Frank–Starling law. However, there is a point at which further increases in end-diastolic volume 
are met with a decrease in stroke volume, labelled ‗volume overload‘. Note also the depressed response of 
the failing heart.  
 
In each of the situations above, we arrive at a position of impaired cardiac performance. 
When this occurs, the heart relies on a series of adaptive mechanisms for the 
preservation of its contractile state. Initially, each of these systems proves beneficial to 
the functioning circulation; however, in the case of chronic heart failure, over time, they 
become maladaptive and detrimental to cardiac function. These mechanisms can be 
divided into two broad groups: intracardiac and extracardiac mechanisms.  
 
Intracardiac mechanisms involve changes to the myocardium on a molecular and 
cellular level. The most obvious of these is ventricular hypertrophy, which develops in 
response to an excessive pressure or volume load.
11
 Haemodynamic overload is thought 
to re-activate growth factors present in the embryonic heart but dormant in the normal 
adult heart,
12
 leading to increased protein synthesis and increased myofibril mass.
13
 This 
is accompanied by an increase in energy demand, met by increased synthesis of 
mitochondria
14
 and increased collagen.
15
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It is easy to see how these adaptive mechanisms prove beneficial to the circulatory 
system, at least in the short-term. Ventricular hypertrophy will increase contractile 
force, with support from more mitochondria meeting the increased energy demands, and 
it is also thought that an increase in collagen may reduce ventricular dilatation. Over 
time, however, there is a shift from compensatory hypertrophy to heart failure, as the 
myocytes deteriorate and die, and the mitochondria are exhausted. Failure of the 
compensatory mechanisms obviously results in impaired cardiac function once again, 
and a downward spiral is set in motion. In addition, the excess collagen starts to impair 
relaxation and ventricular filling, further exacerbating myocardial dysfunction. 
 
So far, this chapter has dealt mainly with the intrinsic features of cardiac physiology and 
pathology, which constitute the haemodynamic model of heart failure. As knowledge of 
heart function and failure has increased, however, it has become evident that 
extracardiac mechanisms are at play, both in the physiological and pathological state. 
Broadly, these mechanisms form the neurohormonal and immunological models of 
cardiac failure. Again, these adjustments that are initially advantageous in maintaining 
adequate cardiac output, ultimately prove to be detrimental. 
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2.4.2 Neurohormonal aspects of heart failure 
2.4.2.1 Sympathetic drive 
The most immediate of these mechanisms is increased sympathetic activity. Primarily in 
response to decreased blood pressure detected by carotid artery baroreceptors, the 
sympathetic nervous system causes rapid vasoconstriction of the arteriolar system 
(causing an increase in arterial blood pressure), vasoconstriction of the venous system 
(increasing venous return), and increased heart rate. However, this control of blood 
pressure is very short lived, since the ‗set-point‘ (the blood pressure at which the 
baroreceptors cause these effects) is reset within 1–2 days.16 In fact, like other 
compensatory mechanisms, this also becomes counterproductive; adults with congestive 
heart failure (CHF) have increased levels of circulating catecholamines, but rather than 
producing the normal inotropic and chronotropic responses, the failing heart is 
relatively insensitive to this stimulation. Again, there is a situation of afterload 
mismatch, where stroke volume does not increase proportionally to the increased 
demands on the myocardium. There is, however, an increase in energy expenditure 
seen, as well as an increase in the likelihood of ventricular arrhythmia, with a 
concomitant negative effect on survival.
17, 18
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2.4.2.2 Renin-angiotensin system 
The other main arm of the neurohormonal response is the renin–angiotensin system. 
Renin release in the kidney is augmented by β1-adrenoceptors in the juxtaglomerular 
apparatus (under sympathetic stimulation), and is further enhanced by activation of 
baroreceptors in the renal vascular bed (in response to decreased blood pressure). Renin 
converts angiotensinogen to angiotensin I, which is subsequently converted by 
angiotensin-converting enzyme (ACE) to angiotensin II, promoting re-absorption of salt 
and water by the tubules. Angiotensin II is also a powerful peripheral vasoconstrictor. 
Decreased arterial pressure and constriction of the afferent arterioles of the kidney 
(under sympathetic drive) also serve to decrease the glomerular filtration rate, which 
decreases urine output. This initial response by the kidneys to falling cardiac output 
causes salt and water retention (thereby augmenting preload). In chronic heart failure, 
angiotensin II stimulates the adrenal glands to produce aldosterone, which further 
increases sodium re-absorption by the tubules, and thereby fluid retention. In addition, 
the increase in sodium ions (and chloride ions) increases the extracellular osmolarity, 
which initiates the secretion of antidiuretic hormone by the hypothalamic-pituitary axis, 
exacerbating fluid retention further. While this may boost stroke volume in the short-
term, long-term fluid overload leads to pulmonary and peripheral congestion.  
 
The role of the renin–angiotensin system is not limited to its effect on the kidney. The 
myocardium itself is capable of synthesizing ACE and angiotensin receptors.
19
 Under 
conditions of heart failure, the myocardium exhibits greater ACE activity. In addition, 
angiotensin II is known to have direct hypertrophic effects on the myocardium,
20
 as well 
as increased collagen production.
19
 This local renin–angiotensin system is now a crucial 
target in the medical therapies of heart failure.  
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2.4.2.3 Natriuretic peptides 
The three natriuretic peptides found in the body (atrial natriuretic peptide (ANP), brain 
natriuretic peptide (BNP) and C-type natriuretic peptide) also have a crucial part to play 
in paediatric heart failure. ANP and BNP are both released from the heart in response to 
myocardial stretch, and act as physiological antagonists to vasoconstriction and sodium 
re-absorption mediated by the renin–angiotensin and sympathetic nervous systems.21 
Plasma levels of N-terminal pro-brain natriuretic peptide (nt-BNP) have been shown to 
reflect the severity of symptoms in heart failure and the impairment in cardiac function 
in children with CHF, and can be used as a marker of the effects of treatment.
22
 
Moreover, natriuretic peptides themselves have been considered as treatments for CHF 
in children. 
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2.4.3 Immunological aspects of heart failure 
The immunological aspects of heart failure are perhaps the least studied and least well 
understood of the three arms in the pathophysiology of heart failure. However, over 
recent years, the importance of the immune system in the progression of CHF has 
become increasingly well recognised. Peptide growth factors have been shown to be 
expressed by cardiac cells,
23, 24
 and have been shown to cause hypertrophy,
25
 illustrating 
that they may well have a role in heart failure and may therefore be a target for future 
therapies. 
 
In addition, inflammatory cytokines are also implicated in the development of heart 
failure. Tumour necrosis factor-α (TNF-α) and interleukin have been shown to depress 
myocardial activity both in vivo and in vitro; they have also been shown to induce 
myocardial apoptosis and promote cardiac hypertrophy and fibrosis.
26
 It is also known 
that levels of TNF-α are increased in patients with heart failure.27 TNF-α inhibition has 
been shown to inhibit myocardial remodelling in rats, promoting a possible concept of 
therapy.
28
 Two proposed agents were etanercept (a recombinant human TNF receptor) 
and infliximab (a chimeric monoclonal antibody to TNF-α); neither, however, has 
shown benefit in clinical trials.
29, 30
  
2.5 DIFFERENCES BETWEEN NEONATAL, PAEDIATRIC AND ADULT 
CARDIAC PHYSIOLOGY  
The vast majority of clinical trials (as well as many physiological and pathological 
studies) in heart failure have taken place in adult populations; the paediatric cardiologist 
is therefore forced to base much of his knowledge on extrapolation from these. It is 
important, however, to bear in mind the axiom ‗children are not small adults‘, and an 
understanding of some of the ways in which paediatric and adult cardiac physiology 
differ is essential if these extrapolations are to be justified.  
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One major difference is the underdeveloped sarcoplasmic reticulum (SR) of the 
neonatal myocyte.
31
 Calcium handling is therefore dependent on greater activity of the 
L-type calcium channel
32
 and the Na+/Ca2+ exchanger,
33
 and it is vital to maintain 
normal ionised calcium levels in children for inotropic therapies to be effective. 
Similarly, calcium channel blockers are capable of producing a profound depression of 
myocardial contractility in the younger heart. 
 
Recently, with greater application of Doppler tissue imaging, there has been interest in 
the biomechanics of myocardial contraction. Of particular significance is the ‗twisting‘ 
of the myocardium during systole, caused by anticlockwise rotation of the apex and 
simultaneous clockwise rotation of the base (when viewed from the apex).
34
 This 
torsion of the left ventricle stores significant energy that is released during the recoil of 
the isovolaemic relaxation stage of diastole, creating suction that is essential for rapid 
early filling of the ventricle. In a recent paper, age-related differences have been 
highlighted in this ventricular torsion: the neonatal heart exhibits relatively little torsion 
compared with adolescents and adults.
35
 Furthermore, although torsion continues to 
increase throughout life, there is a slowing in recoil that may contribute to diastolic 
dysfunction in the elderly. It is important to consider these differences when thinking 
about diastolic dysfunction in children. 
2.6 MEDICAL MANAGEMENT OF PAEDIATRIC HEART FAILURE 
Aside from limited surgical interventions (either in congenital heart disease, or in the 
case of heart transplantation), the main approach to the treatment of paediatric heart 
failure is the use of drugs. However, it is important that other modalities of treatment 
are not forgotten. The most crucial of these is nutrition; it is essential that adequate 
nutrition be supplied to the child in heart failure, but excess sodium should be avoided. 
In the case of infants, reduced-volume, high-energy feeds may be required in order to 
supply the body with the increased energy demands of heart failure, without 
overburdening the circulation with excess fluid. 
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Previously, with limited understanding of the pathophysiology of heart failure, therapies 
were aimed at improving myocardial function directly. Although this must still be the 
approach in the acute setting, there is evidence that this strategy worsens both long-term 
morbidity and mortality.
36, 37
 As knowledge has increased, greater importance has been 
placed on preventing the deleterious effects of long-term compensatory mechanisms. 
With a better understanding of the underlying pathophysiology, the physician is now in 
a better position to select the appropriate drug class for an individual patient, not only to 
improve cardiac function in the acute setting, but also to prolong the long-term viability 
of the myocardium.  
2.6.1 Diuretics 
Diuretics have long been used in the treatment of heart failure in both adults and 
children, for obvious reasons. They are certainly indicated in patients exhibiting 
symptoms or signs of congestive heart failure (CHF), such as dyspnoea, and produce 
symptomatic benefits more rapidly than any other drug for heart failure.
38
 The reduction 
in preload not only decreases pulmonary congestion, but also leads to a reduction in 
myocardial wall stress, which is a potent stimulus for remodelling. Loop diuretics also 
cause pulmonary vasodilatation, with further symptomatic relief. However, they possess 
the detrimental side-effect of neurohormonal activation;
39
 for this reason, they may be 
relatively contra-indicated in patients without symptoms of congestion. A further issue 
is resistance to diuretics with long-term use in heart failure, which is associated with an 
increase in morbidity and mortality.
40
 In this case, the European Society of Cardiology, 
the American College of Cardiology and the American Heart Association recommend 
adding metolazone (a thiazide diuretic) to a loop diuretic in order to promote sodium 
loss at different portions of the nephron,
38, 41
 although it is only infrequently used in 
children. 
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2.6.2 Spironolactone 
Spironolactone is an aldosterone receptor antagonist. It has only a mild diuretic therapy 
(as its site of action is the distal nephron, by which point much of the sodium of the 
filtrate has been re-absorbed), and was initially given concurrently with other diuretics 
to minimize electrolyte disturbance. However, the Randomized Aldactone Evaluation 
Study (RALES) found a 31% reduction in death from cardiac causes, and a reduction in 
hospitalization and symptoms in adults with heart failure treated concomitantly with an 
ACE inhibitor.
42
 One of the possible explanations for this effect is that spironolactone 
may limit excessive extracellular matrix turnover, thereby reducing fibrosis and 
remodelling.
43
 
2.6.3 Angiotensin converting enzyme (ACE) inhibitors 
ACE inhibitors were a significant addition to the treatment of paediatric heart failure in 
the 1990s. They lower aortic pressure and systemic vascular resistance, and lower left 
and right atrial pressures in children with heart failure, without affecting pulmonary 
vascular resistance significantly. ACE inhibitors have also been shown to lower 
circulating norepinephrine levels, thereby decreasing the effects of the neurohormonal 
model of heart failure, and stimulate prostaglandin synthesis. Several studies have 
shown a decrease in mortality and morbidity in adult patients.
44, 45
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2.6.4 β-blockers 
The rationale behind the use of β-blockers in heart failure is to prevent and reverse 
adrenergically mediated intrinsic myocardial dysfunction and remodelling,
46
 one of the 
initially compensatory but ultimately deleterious factors in the progression of heart 
failure. Large multi-centre trials in adults have shown their benefit in morbidity and 
mortality in heart failure.
47-49
 Disappointingly, the paediatric carvedilol study showed 
no benefit of carvedilol versus placebo on clinical outcomes in children with 
symptomatic systemic ventricular systolic dysfunction and heart failure.
50
 The authors 
of the study have implicated a higher than expected placebo response rate, and a 
possible interaction between systemic ventricular anatomy and primary outcome as 
possible reasons for the disappointing result. In contrast, however, in a study on nine 
paediatric patients with dilated cardiomyopathy, carvedilol was found to significantly 
reduce neurohormonal activity (reduced renin–angiotensin system activation, reduced 
norepinephrine, aldosterone and dopamine) and improve left ventricular ejection 
fraction, with significant reductions in ventricular diameters.
51
 The differences in the 
conclusions from these two articles further illustrate the difficulties associated with 
randomised controlled trials in paediatric cardiology. Despite this, β-blockers remain an 
important treatment in paediatric heart failure. 
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2.6.5 Digoxin 
The use of digoxin in heart failure dates back over 200 years. It is a cardiac glycoside 
with a positive inotropic action, as well as a negative chronotropic action (by slowing 
conduction at the atrioventricular node). By inhibiting the Na+/K+-ATPase pump, 
digoxin leads to an increase in intracellular sodium, followed by inhibition of the 
Na+/Ca2+ exchanger, and therefore an increase in intracellular calcium, thereby 
increasing contractility. In normal subjects, this increase in contractility is offset by an 
increase in systemic vascular resistance, and thus digoxin leads to no change in cardiac 
output. However, in patients with systolic impairment (in sinus rhythm), digoxin does 
produce an increase in left ventricular ejection fraction.
52
 Digoxin has also been shown 
to possess neurohormonal effects, including lowering norepinephrine levels
53
 and 
sympathetic tone.
54
 Recently, however, its use has become controversial
55
 and its 
prescription has been limited in favour of β-blockers and ACE inhibitors, both of which 
have been proven to decrease mortality in randomised clinical trials. Digoxin has not 
been proven to reduce mortality in any age group, and shows little positive benefit in 
children with normal systolic function (for instance, children in heart failure secondary 
to shunt lesions).
56
 However, a recently published Cochrane review of digoxin use in 
adults concluded that digoxin did have beneficial effects in treating symptomatic 
patients with heart failure, especially as an add-on in patients for whom a regimen of 
diuretics, ACE inhibitors and β-blockers has failed.57 
2.6.6 Nesiritide 
Nesiritide is a recombinant b-type natriuretic peptide that was shown in multiple clinical 
trials to be of benefit in the treatment of decompensated heart failure in adults.
58
 Early 
studies in children showed improved diuresis and natriuresis in those already on 
inotropic support.
59, 60
 However, concerns over increased mortality, increased renal 
failure and cost have severely tempered this early enthusiasm, and it cannot currently be 
recommended for use in paediatric heart failure.
61
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2.6.7 Statins 
The use of statins (3-hydroxy-3methylglutaryl-CoA reductase inhibitors) in 
cardiovascular disease to lower cholesterol has been universal practice for many years. 
Statins are not currently used regularly in the treatment of paediatric heart failure. New 
evidence of the benefits of their use in heart failure patients with normal cholesterol 
levels indicate a potential broadening of the indications of their use. They have been 
shown to improve endothelial function and neurohormonal imbalance in patients with 
non-ischaemic heart failure and normal cholesterol levels.
62
 Simvastatin has been shown 
to improve ejection fraction and improve symptoms compared with placebo in Japanese 
adults with dilated cardiomyopathy,
63
 as well as improvements in endothelial function 
(measured by flow-mediated dilatation of the brachial artery). In the same study, levels 
of TNF-α, BNP and interleukin-6 were lower in those patients receiving simvastatin; a 
connection which the authors have suggested may be the mechanism for the clinical and 
echocardiographic improvements. An interesting preliminary report into the use of 
statins in diastolic heart failure has also strengthened the cause for their extended use in 
adults. In a trial comparing statins, β-blockers, ACE inhibitors, angiotensin-receptor 
blockers and calcium blockers in patients with diastolic heart failure (with an ejection 
fraction of ≥50%), only statin therapy was linked to a substantial improvement in 
survival.
64
 In this publication, the authors postulated various possible mechanisms to 
explain their results, including anti-inflammatory effects, anti-oxidant effects, protection 
against left ventricular remodelling, antihypertensive effects and improvements in 
arterial distensibility. 
2.7 CONCLUSION 
As knowledge of the pathophysiology of heart failure has grown, theoretical advances 
in treatment have come to light. Although not all of these have been shown to have 
clinical benefit, others have become invaluable means of combating heart failure in 
children. However, the lack of clinical trials in the paediatric population requires that 
treatment protocols are largely based on extrapolation from adult studies, which may 
not always be wholly justified. There remains a pressing need for these challenging 
studies to be organised. 
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2.8 INTRODUCTION – PAEDIATRIC HEART TRANSPLANTATION 
Heart transplantation remains the only realistic therapeutic option for children with end-
stage heart disease. Though the first paediatric heart transplant was performed by 
Kantrowitz in New York in 1967,65 only three days after Barnard‘s celebrated first adult 
transplant, it was soon understood that the discipline was not a mere extension of 
transplantation in adults, but rather a distinct clinical entity with its own set of 
principles, techniques and goals. Of course, there is much overlap with adult 
transplantation, and much of what we know and practice is a direct extrapolation of that 
much larger experience. However, although surgical techniques, post-operative 
intensive care and on-going pharmacological management share much in common 
between the age groups, there are vital differences that must be taken into account if a 
centre is going to produce a successful paediatric transplant programme. 
2.8.1 Recipient population 
It is important to state that paediatric heart transplantation is itself a very heterogeneous 
sub-specialty. Whereas approximately 90% of adult transplants are performed for 
cardiomyopathy (either ischemic or non-ischemic),
66
 up to one in three paediatric 
recipients has a diagnosis of congenital heart disease;
67
 that figure rises to almost 60% 
in infant recipients (Figure 2.3). The use of the word ―diagnosis‖ in the singular form is 
somewhat of a misnomer, however, since this sub-group of patients is further sub-
divided into a wide variation of congenital heart defects, with the possibility of multiple 
previous surgical interventions and wide diversity in clinical status. This variability in 
anatomic substrate must be thought about carefully and on an individual by individual 
basis by the surgical team prior to heart transplant listing; it is also accompanied by 
variability in physiological status that requires skilful management by the anaesthetic 
and intensive care specialists. Further complexity arises from the significant differences 
between neonates, young children and adolescents, again with regards to anatomy and 
physiology, but also in regard to psychology and social background. In addition, 
patients requiring heart transplantation in childhood often have co-existing conditions or 
syndromes that must be considered throughout the transplant process. 
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Figure 2.3 ISHLT figures displaying diagnosis of patients coming to transplant from 2000-2011, 
grouped by age. CAD – coronary artery disease. 
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2.8.2 Worldwide figures 
With this heterogeneity in mind, paediatric transplant teams have been set up in many 
centres worldwide as distinct entities, with obvious benefits from the sub-specialization. 
However, the experience of these teams is generally much less than that of their adult 
counterparts. The latest figures from the International Society of Heart and Lung 
Transplantation reveal that only a quarter of European paediatric transplant centres 
performed more than 10 per year since 2000,
67
 compared to 60% of adult centres.
68
 Low 
volume of cases is known to be a risk factor for mortality post-transplantation, and it is 
easy to understand how increased experience and familiarity of every aspect of 
transplantation would lead to a more successful programme. The small numbers of 
procedures per centre also greatly limit both quantity and quality of research 
possibilities, yet this is counterbalanced by effective multi-centre clinical audit and 
research such as with the Paediatric Heart Transplant Study Group. However, even with 
these caveats, complications and complexities, paediatric heart transplantation has 
significantly better survival rates than adults (Table 2.1). 
 
Age group Median survival worldwide (years) 
Infants 19.2 
Children 15.6 
Adolescents 11.9 
18-29 years 12.2 
60-69 years 8.9 
 
Table 2.1 Latest ISHLT figures of overall survival by age at transplantation.
67
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One further important difference between paediatric and adult heart transplantation is 
how to define success for the paediatric transplant programme and for the individual 
patient. If a 55-year-old man with coronary artery disease survived 15 years after 
transplantation, it would be considered by many patients and health care providers alike 
as a successful and worthwhile intervention with obvious benefit to the patient and 
society as a whole. Although the success and worth of 15-year survival following infant 
transplantation could never be questioned, the prospect of re-transplantation or death in 
adolescence or early adulthood invites further philosophical, ethical and economic 
questions. Although difficult, these issues must be discussed with any prospective 
patient and family, to allow careful consideration before agreeing to be transplant listed. 
2.8.3 Indications 
Improvements to every stage of transplantation have greatly increased the success of the 
procedure, both in terms of longevity and quality of life of the childhood recipients. 
Simultaneously, there have been great strides made in the treatment of heart failure and 
the surgical treatment of congenital heart disease, allowing transplantation to be 
postponed or completely avoided in some patients. With this in mind, in 2007 the 
American Heart Association Council on Cardiovascular Disease in the Young 
developed a document describing the current indications for paediatric heart 
transplantation (Table 2.2).
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Predictably, the guidelines are largely based on clinical expert opinion, rather than 
large, multi-centre randomized controlled trials, due to the paucity of these in such a 
small field. They divided their indications into three classes:  
 Class I where evidence or general opinion suggests that transplantation would be 
useful and effective 
 Class II where there is conflicting evidence or a divergence of opinion, further 
subdivided into Class IIA (weight of evidence/opinion is in favour) and Class 
IIB (usefulness is less well established) 
 Class III where evidence or general opinion is that transplantation is not useful.  
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Class I Class IIA Class IIB Class III 
•Stage D heart failure 
(CM or CHD) with 
systemic ventricular 
dysfunction 
•Stage C heart failure 
with: 
i. severe limitation of 
exercise and activity 
(peak max. oxygen 
consumption <50% 
predicated), or 
ii. significant growth 
failure, or 
iii. untreatable life 
threatening arrhythmias 
•Stage C heart failure in 
RCM with reactive 
pulmonary hypertension 
•Stage C heart failure 
with reactive pulmonary 
hypertension and 
potential of developing 
fixed PVR 
•Anatomical or 
physiological conditions 
likely to worsen 
prognosis of 
univentricular CHD 
which can lead to HTx 
as primary therapy  
•Anatomical or 
physiological conditions 
likely to worsen 
prognosis of operated 
CHD without impaired 
ventricular function 
 
 
Efficacy of HTx not 
established for  
•Patients with history 
of:  
i. Hepatitis B or C or 
HIV 
ii. Use of tobacco or 
illicit drugs, or alcohol 
abuse 
iii. psychological, 
behavioural disorders, 
poor family support 
structures, documented 
noncompliance with 
previous therapies 
  
HTx not efficacious: 
•Severe irreversible 
disease in other organs 
•Severe irreversible, 
fixed elevation of PVR 
•Severe hypoplasia of 
central branch 
pulmonary arteries 
 
 
 
Table 2.2 Indications for paediatric heart transplantation. CM – cardiomyopathy, CHD – congenital 
heart disease, RCM – restrictive cardiomyopathy, PVR – pulmonary vascular resistance, HTx – heart 
transplantation. 
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It is important to stress that heart transplantation should not be used as the primary 
therapy for any infant with congenital heart disease without the presence of concomitant 
coronary, valvular or ventricular impairment. It is, however, reasonable to consider 
transplantation in the setting of previously repaired congenital heart disease without 
ventricular dysfunction if there is risk of developing fixed raised PVR that could 
preclude future transplantation, severe aortic or systemic valve insufficiency, severe 
cyanosis, persistent arrhythmia or persistent protein losing enteropathy.  
 
2.8.4 Timing of listing for transplant of ambulatory patients 
While increasing proportions of heart transplants are performed in very ill patients on 
high dose inotropes or mechanical support, some patients are transplanted while still 
ambulatory and at home. The timing of listing for ambulatory patients is difficult and 
controversial, even in adult cardiology. Many paediatric cardiologists base timing on 
evidence of left ventricular systolic dysfunction and symptoms of heart failure. Severity 
of ventricular dysfunction has been found to be predictive of outcome in some studies 
but not in others. Symptoms appear to provide poor prognostic capability too, because 
even asymptomatic children with incidental discovery of cardiomyopathy can have a 
poor prognosis. Finding ways to identify those patients with the highest risk of clinical 
deterioration and/or death would greatly assist in clinical decision-making, including the 
indication and prioritization for transplant. 
Chapter 2  Paediatric heart failure & transplantation 
 32 
2.8.4.1 Exercise testing 
Extensive evidence supports the use of cardiopulmonary exercise testing as a tool to 
select patients with increased short-term mortality that should be offered 
transplantation. Besides peak oxygen uptake, several additional variables, for instance 
ventilatory efficiency, have been shown to have high prognostic value in adults with 
heart failure. However, despite widespread use in the adult population, information 
regarding the practical clinical value of exercise testing as a prognostic tool in 
paediatrics is very limited. At Great Ormond Street, exercise testing is possible in 
children over 10 years of age and sometimes younger. Data acquired here is broadly 
supportive of a peak oxygen consumption of less than 50% of predicted for age, 
although peak blood pressure response to exercise has also been found to be an 
important prognostic test.
70
 
  
Exercise testing is complicated in congenital heart disease. Peak heart rate appears to be 
a useful prognostic marker. Oxygen consumption and ventilatory efficiency are also 
useful. However, the values at which transplantation should be considered vary with the 
type of congenital heart disease. Patients with a Fontan circulation have much lower 
baseline levels of oxygen consumption and ventilatory efficiency. A simple 6-minute 
flat walking test is still valuable in congenital heart disease. 
 
For younger children, pre-school age and infants, exercise testing is impossible. It is in 
this age group that biomarkers of heart failure are particularly useful. In patients with 
chronic heart failure, B-type natriuretic peptide level of over 300 pg/ml may be 
predictive of poor outcome in paediatric cardiomyopathy.
71
 Other biomarkers are 
currently being assessed.
72
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2.9 SPECIFIC PRE-TRANSPLANT ISSUES 
2.9.1 Transplantation for congenital heart disease 
Transplantation for congenital heart disease illustrates best many of the peculiarities of 
heart transplant in the paediatric age-group. As experience with paediatric transplant has 
grown, the boundaries of what anatomy is considered transplantable have extended to 
the point now that the only contraindications from a purely anatomical point of view are 
severe pulmonary artery hypoplasia and pulmonary vein stenosis. However, these may 
be correctable by heart-lung transplantation or using extended donor pulmonary arteries 
for pulmonary hypoplasia. 
 
Concurrently, improved conventional surgical techniques have led to the treatment of 
more and more congenital heart disease without the need for early transplantation. 
However, these methods, along with the success of non-curative surgical procedures 
such as the Fontan pathway, have only postponed the need for transplant in many 
patients, reducing strain on the youngest, most scarce donors, but in many cases adding 
to the waiting list in later childhood. In reality, these improvements may have even 
increased the overall numbers of potential recipients as many babies would previously 
have died during neonatal operations, or on neonatal transplant waiting lists. Many of 
these children are now surviving infancy, but with circulatory systems that are destined 
to fail at some point, and by the time a heart transplant is required, some families are 
finding transplantation a more attractive option, and palliative care strategies less so. 
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In most registries, congenital heart disease remains a risk factor for transplantation.
67
 
Attrition is early and related to the complexity of the reconstruction. Yet it would be 
wrong to be uniformly negative about transplantation for congenital heart disease. 
Registry data has shown that transplantation following previous Senning or Mustard 
procedures can now be achieved with a low mortality. Previously palliated infants and 
young children with a Glenn circulation also appear to have relatively low risk. 
However, it is the Fontan patients who represent the highest risk with a recent paper 
showing a relative risk of death of 8.6 compared to other congenital operations.
73
 The 
Fontan patients often have liver or renal problems and may suffer more infections by 
virtue of protein losing enteropathy and lymphopenia. Protein losing enteropathy 
increases the risk of transplant, perhaps because it may be a marker of increased 
pulmonary vascular resistance. Resistance is hard to calculate in the Fontan patients 
with multiple sources of pulmonary blood supply, pulmonary arteriovenous 
malformations, collaterals and fenestrations. 
 
For all congenital patients it is obvious that risk can be reduced by having an 
experienced congenital heart surgeon perform the operation with appropriate anaesthetic 
and intensive care teams. This is particularly important in adult congenital heart disease, 
where few adult transplant teams have extensive congenital experience. 
 
Since the lifespan of a transplanted organ is limited, no potential recipient should be 
transplanted too early. The aim of paediatric programmes is often to delay 
transplantation for as long as possible by optimizing medical management. However, 
this delay must not be at the expense of other organ damage (most notably renal failure 
or cirrhosis in Fontan patients), increasing pulmonary resistance or inducing HLA 
sensitisation by virtue of blood transfusions. Any of these complications of delaying 
transplant may reduce the success of future transplantation, and have the effect of an 
overall decrease in life expectancy. 
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Prior to listing for transplantation, detailed scanning of the heart and pulmonary 
vasculature with an appropriate combination of echocardiography, angiography, CT or 
MR must be undertaken to ensure that the anatomy is favourable. These scans must be 
available to the surgeon before accepting an offer of a potential organ, in order that he 
can request extended portions of the great vessels which may be required to facilitate 
non-standard anastomoses. Since it is likely that other organs may be being harvested 
from the same donor, it is important for the cardiac surgeon to speak to other transplant 
teams to enable the most judicious use of donor vessels, or perhaps arrange for 
alternative tissue to be collected. For instance, if the heart transplant surgeon feels he is 
unable to harvest enough of the pulmonary arteries for a particular recipient, he may be 
able to use donor pericardium or descending aorta. 
2.9.2 Surgical technique 
Heart transplantation is performed via a median sternotomy. In patients with congenital 
heart disease, previous sternotomies may have resulted in dense mediastinal adhesions 
which can cause heavy intra-operative haemorrhage. Significant bleeding can also occur 
from substernal great vessels or additional collateral vessels – the results of years of 
cyanosis. Under such circumstances, some surgeons may opt to expose the femoral 
vessels prior to sternotomy to facilitate emergency femoro-femoral bypass should the 
need arise. 
 
Venous cannulae are placed in the SVC and IVC, and an arterial cannula in the 
ascending aorta at the level of the innominate artery, facilitating cardiopulmonary 
bypass. Body cooling is carried out to 32°C, unless deeper hypothermia is required in 
the case of longer predicted operating times, for instance when additional correction of 
complex heart defects is necessary (e.g. the abnormal venous anatomy seen in patients 
with isomerism of the atrial appendages); in such instances, the body is cooled to a 
nasopharyngeal temperature of 18°C. It is essential to anticipate long recipient 
dissection times to closely coordinate with the arrival of the donor organ, thereby 
minimising ischaemic times. 
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The aorta is subsequently cross-clamped, and the right and left atrial walls are then 
divided close to the atrioventricular groove and the atrial septum, being careful to leave 
a sufficient rim of atrial tissue for later suturing of the donor graft. A similar cuff of 
right atrial tissue is left following transection of the caval veins, and the rest of the right 
atrium removed. The great arteries are transected just superior to their valves; further 
surgical modification of the remaining tissue is often required to compensate for any 
discrepancy in size between the donor and recipient vessels. The recipient heart is now 
completely free, and is removed. 
 
The donor heart is placed over the left side of the divided sternum, parallel to the 
remnant of the excised recipient heart. The graft is positioned in such a way that the left 
atrial surfaces of the donor and recipient hearts are in contact, with leftwards rotation of 
the donor heart resulting in its posterior surface facing anteromedially. The two left atria 
are then sewn together with continuous polypropylene, starting at the base of the left 
atrial appendage of the donor heart close to the caudal end of the recipient left upper 
pulmonary vein. The anastomosis continues around the superior and inferior walls of 
the left atrium onto the atrial septum. The Great Ormond Street surgical team favour a 
bicaval anastomosis for the systemic venous pathways, with both caval veins being 
sutured separately. However, due to the risk of kinking or purse-stringing of the SVC, 
right atrial anastomosis is sometimes preferred in small infants. 
 
Connection of both great arteries is then performed. Following meticulous de-airing of 
the left heart, the aortic cross-clamp is removed and rewarming of the heart can begin. 
Similarly, the caval snares are removed and the right heart is de-aired. In order to guide 
intensive care decisions – particularly concerning the use of post-operative ventilation 
and inotropic drugs – monitoring lines are placed in the left atrium and the pulmonary 
artery, and right atrial and right ventricular pacing wires are inserted as a precaution 
against the effects of post-operative arrhythmias, such as heart block. As the heart 
rewarms, spontaneous re-activation occurs; direct application of a DC current is needed 
in the case of ventricular fibrillation. As graft function improves, the patient can be 
weaned from cardiopulmonary bypass, and transferred back to the intensive care unit. 
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2.9.3 Pulmonary vascular resistance 
The assessment of pulmonary vascular resistance is particularly crucial in order to 
reduce the rate of right heart failure post-transplant,
74
 but it can be technically difficult, 
particularly in congenital heart disease. In general the guidelines document referred to 
above advises that transplantation is possible if PVR can be reduced using pulmonary 
vasodilators to a transpulmonary gradient of under 15mmHg and a PVR of ≤ 6 Woods 
units.m
2
.
69
 There is a tendency for paediatric centres to push the boundaries of 
transplantable PVR, and some units will take on children with resistance higher than 
this, but it is clear that risk is increased. A long period of inotrope or vasodilator therapy 
may reduce PVR, as may a period of mechanical support by reducing left ventricular 
end diastolic pressure. 
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2.9.4 Mechanical Support 
Traditionally, paediatric units offered only ECMO support as a bridge to transplant, as 
most ventricular assist devices were not suitable for small children. This strategy 
allowed only a short time for support before serious complications ensued. The 
development of a pneumatic assist device suitable for children (the Berlin Heart) has 
allowed long-term bridge to transplantation in young children.
75
 Successful support is 
possible for many months, although few children are discharged from hospital. Most 
experience has been obtained in children with dilated cardiomyopathy who are older 
than 1 month of age. Usually the device is implanted in children with progressive 
cardiac failure and inotrope dependency. Little data exists on support for very young 
children less than 4 kg. It seems likely that the neonatal group will be more difficult to 
manage with the small 10ml pumps and anticoagulation complexities increasing their 
risk of thrombo-embolic complications.
76
 Typically the device is used as a bridge to 
transplant although there are reports of use as bridge to recovery, and it has been used in 
myocarditis. In general, fulminant myocarditis is still treated with ECMO in most 
centres although this may change as experience with the Berlin Heart increases. 
However, ECMO does avoid a left ventricular scar. Conversion from ECMO to Berlin 
Heart is often performed, although primary implantation of Berlin Heart is preferred in 
most units. The use in single ventricle circulations and particularly the Fontan 
circulation also appears more complex, but possible.
77, 78
 The limited data available 
does suggest a higher mortality in the single ventricle group. However, the recent huge 
increase in Berlin Heart insertion in the USA illustrates the success of this device. 
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Figure 2.4 ISHLT figures showing use of mechanical support prior to paediatric heart 
transplantation from 2005-2010. ECMO – extra-corporeal membranous oxygenation; VAD – 
ventricular assist device; TAH – total artificial heart. 
 
2.9.5 ABO incompatibility 
Compared with adult transplantation, the prospective donor pool of hearts suitable for 
infant recipients is small. Infants with blood group O have a further reduced donor pool. 
This imbalance has prompted advances in transplanting across blood groups – the so-
called ABO-incompatible transplant. In adults, heart transplants across ABO blood 
groups have occurred only by mistake, with high rates of both hyperacute rejection and 
mortality. 
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In contrast to mature adult immune systems, however, infants have very low levels of 
isohemagglutinins, allowing the possibility of transplanting an organ of blood type B, 
say, into a recipient of type A. In 1996, Prof. Lori West led the team that performed the 
first intentional heart transplant across an ABO incompatibility.
79
 The recipient was a 
25 day-old baby with hypoplastic left heart syndrome of blood group O that received an 
organ of blood group AB. During cardiopulmonary bypass, plasma exchange was 
performed until the levels of isohemagglutinins were non-detectable. In the paper 
reporting the first ten ABO-incompatible transplants, rates of mortality, rejection and 
morbidity were equivalent to ABO-compatible transplants, with two deaths and one 
other graft loss unrelated to ABO activation,
79
 data which has recently been supported 
with excellent long-term outcome.
80
 It is thought that donor-specific B-cell elimination 
results in immunological tolerance in recipients of ABO-incompatible hearts. In order to 
ensure the on-going success of the graft, future transfusion of blood products must 
occur according to strict criteria (Table 2.3). The exact age and level of 
isohemagglutinins that are acceptable for ABO mismatch transplant are unclear but an 
isohemagglutinin dilution of 1:16 is used at Great Ormond Street as a cut-off value, and 
few such transplants have been performed over the age of 2 years. 
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Donor Blood 
Group 
Recipient Blood 
Group  
Indicated 
plasma 
Indicated red 
cells 
Indicated 
platelets 
AB O AB O AB 
B O AB or B O AB or B 
A O AB or A O  AB or A 
AB B AB O or B AB 
A B AB O or B AB 
AB A AB O or A AB 
B A AB O or A AB 
 
Table 2.3 Required blood groups for transfusion after ABO incompatible paediatric heart 
transplantation. 
2.9.6 Lymphocytotoxic antibodies 
Another problem in paediatric transplantation is the presence of pre-existing human 
leukocyte antigen (HLA) antibodies, which have been linked to increased hyperacute, 
cellular and humoral rejection, and increased mortality post-transplant.
81
 There are 
several factors that cause the formation of such antibodies. However, most antibodies 
are formed in response to blood products (particularly white cells and platelets) or 
homograft tissue. Thus, prior HLA sensitization is much more common in children who 
have undergone surgery for congenital heart disease, or those who have required 
mechanical support. For children on longer term mechanical support the ―prophylactic‖ 
use of supplements of iron, folic acid and erythropoietin may avoid blood transfusion. 
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When a patient is sensitized, a prospective cross match between donor and recipient 
serum prior to transplantation would be the perfect solution, but it is time-consuming – 
which limits the geographical area from which a sensitized recipient can receive an 
organ. Alternatively, it is possible to test antibodies against specific HLA antigens, 
thereby facilitating a ―virtual‖ cross-match once a potential donor has been found. 
Although this will not be as specific as a prospective cross match it has been used safely 
in both adult and paediatric transplantation.
82
 
 
It is also possible to reduce the level of HLA antibodies prior to transplantation. 
Strategies for de-sensitization include intravenous immunoglobulin, methotrexate, 
mycophenolate mofetil, cyclophosphamide and rituximab, and newer monoclonal 
antibodies to plasma cells, to lower the level of PRA prior to transplantation.
81, 83, 84
  
However, there has not been uniform success with these strategies and there is often a 
limited window of low antibody levels in which transplantation can be performed. This 
has led some North American centres to transplant across the HLA barrier using intra-
operative plasma exchange, and post-operative plasmapheresis with other antibody 
reducing strategies. Results are still at a preliminary stage, but it appears that primary 
graft failure can often be avoided, and while antibody mediated rejection is common, it 
may resolve with possible accommodation to the antibody. The long-term consequences 
of this strategy are as yet unknown. 
2.10 POST-TRANSPLANT LIFE 
2.10.1 Immunosuppression  
It does appear that acute cellular rejection, in particular that associated with 
hemodynamic compromise, is becoming less common. This may be the result of newer 
drugs and increased experience. Over the last decade or so, there has been a gradual 
shift towards using induction therapy in paediatric heart transplantation, with current 
levels at about 70%.
67
 As opposed to adult practice (which has similar overall levels of 
induction use), antithymocyte globulin remains the preferred agent in children, although 
the proportion of centres using an interleukin-2 receptor antagonist such as basiliximab 
is increasing.
85
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Maintenance therapy is most commonly a combination of a calcineurin inhibitor and 
cell cycle inhibitor. Tacrolimus has become the calcineurin inhibitor of choice in two-
thirds of paediatric patients,
67
 taking over from ciclosporin at least in part due to the 
latter‘s unwanted side-effect profile of hirsuitism and gingival hypertrophy, which can 
lead to problems with compliance in paediatric patients. Cell cycle inhibitors are used 
by 88% in the first year, with mycophenolate mofetil (MMF) the most common, being 
used in 70% of those children; approximately one-third of all patients are prescribed it 
in combination with tacrolimus. This figure is slightly less than the equivalent value in 
adults, approximately half of whom are taking tacrolimus and MMF in combination.  
Steroids still hold a place in paediatric practice, particularly in the first year post-
transplant, and in the treatment of rejection. The proportion of patients using steroids is 
slightly less than in adults, with 55% of children taking prednisolone at one year; by 
five years post-transplant this figure has fallen to less than 40%.
67
 
2.10.2 Renal disease 
Chronic use of calcineurin inhibitors induces renal dysfunction. This is clearly crucial in 
paediatrics where patients are still young and hopeful of a second heart transplant when 
the first one eventually fails. Nephrotoxicity can be reduced by using lower levels both 
early post-transplant and later in the recipient‘s course. The main paediatric use of 
sirolimus and everolimus has been in children with impaired renal function post-
transplant along with reduced doses of calcineurin inhibitors. Others have used 
calcineurin free regimes.
86
 The latter may be associated with an increased risk of 
rejection and greater surveillance with biopsy and non-invasive testing is needed.  
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2.10.3 Lymphoma 
Unlike adult transplant medicine, paediatric transplant teams do not have to deal with a 
wide range of malignancies post-transplant. Even skin malignancies are uncommon in 
children, but this does not preclude the need for sun protection and surveillance. The 
main malignancy in children post-transplant is lymphoma. Usually, this is a B cell 
lymphoma and is triggered by Ebstein Barr Virus. Surveillance using quantitative PCR 
for the virus may give early warning of incipient lymphoma and many teams will 
reduce immunosuppression when viral loads are high. The risk of lymphoma appears 
greater in children that seroconvert post-transplant. The site of the lymphoma varies but 
is often in the gut (typically associated with a low albumin), lungs (where chronic chest 
infections may be wrongly diagnosed) or tonsils. Tissue diagnosis is usually needed. 
Treatment can be simply with reduction of immunosuppression but rituximab is also 
increasingly used in the initial stages. Treatment may escalate to conventional 
chemotherapy and even specific T cells have been generated to destroy the EBV 
associated B cells.  
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2.10.4 Cardiac allograft vasculopathy  
Like adults, the major obstacle to late patient survival in paediatric heart transplantation 
is cardiac allograft vasculopathy (CAV), an accelerated form of obliterative 
cardiovascular disease (Figure 2.5). CAV causes considerable morbidity and mortality, 
affecting approximately 50% of patients 5 years post-transplant. It is the leading cause 
of death in adult patients more than 5 years post-transplant,
87
 and in children more than 
3 years post-transplant.
88
 As it is accompanied by remodelling and compensatory 
luminal dilatation in the early phases, it is best diagnosed not with conventional 
angiography, but with intravascular ultrasound. However, since this technique is not 
widely available in children, it is likely that the prevalence of the disease has been 
underestimated. Moreover, once a diagnosis of CAV has been made, graft survival is 
limited to 50% at 2 years.
89
 It is thus the greatest limitation on long-term outcome, and 
remains the most pressing problem for transplant programmes worldwide. The cause 
remains unknown but conventional risk factors such as smoking, hypertension, diabetes, 
hypercholesterolemia, and obesity are less of a problem in paediatrics than in adults. In 
children chronic viral infection such as cytomegalovirus and recurrent acute or chronic 
cellular rejection appear important. It does seem that chronic inflammation is important 
in the development of CAV. 
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Figure 2.5 Intravascular ultrasound images of the left anterior descending coronary artery of the 
same patient taken 1 and 2 years post-transplant. The figure on the left shows a relatively healthy 
artery, with good lumen size, and only a small amount of intimal thickening in the upper left quadrant. 
The figure on the right shows the effective lumen now decreased to only slightly larger than the 
ultrasound probe, with the rest of the artery replaced by grossly thickened intima. The patient had 
clinically significant CMV disease during the period between the images. 
 
Current treatment is severely limited. The use of statins has been shown to improve 
outcome after transplantation, perhaps in part due to their anti-inflammatory properties, 
as well as a lipid lowering effect. They are recommended as a preventative measure in 
all adult transplant recipients. We have used pravastatin in all children including infants 
with few problems. Pravastatin has the advantage of not interfering with cytochrome 
p450 and thus calcineurin inhibitors. Reversal of CAV is much harder. Sirolimus use 
has been used as an antiproliferative in both adults and children. Ultimately, however, 
many patients with CAV face the prospect of re-transplantation relatively soon after 
diagnosis. In the paediatric age group, it is the most common indication for re-
transplantation, making up just over half of all re-transplants.  
 
Intima
Intracoronary blood
IVUS probe
Intima
Intracoronary 
blood
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2.10.5 Psychological, developmental and behavioural issues 
Ultimately, the success of individual transplants and the programme as a whole depends 
on well-informed, psychologically stable and motivated patients. In paediatric transplant 
these are even more vital as the advent of adolescence often magnifies any 
psychological stressors. The prevalence of behavioural problems in post-transplant 
children is over 25%, a frequency that exceeds that of children following conventional 
cardiac surgery.
90
 Moreover, the effects of such problems, in particular non-compliance 
with immunosuppression, are potentially more serious. It is therefore of paramount 
importance to make psychological and social assessments of potential recipients prior to 
transplant, and try to address any issues that may arise. 
 
Cognitive development of children following cardiac transplant is obviously an 
important outcome variable. Many studies have tried to evaluate accurately the impact 
of transplantation. In general, the transplant group has mean mental and psychomotor 
scores at the low end of the normal range.
90, 91
 Many factors are postulated as causes for 
this discrepancy between the transplant and healthy population, including 
hospitalization, missed school, cardiopulmonary bypass and the side effects of post-
transplant drugs. Encouragingly, the vast majority of paediatric heart transplant 
recipients should look forward to reintegrating fully into normal schooling and social 
activities. 
 
Adherence to post-transplant medication regimens is not universally high amongst 
childhood recipients, and it is commonly cited as a cause of acute rejection and death, 
particularly amongst teenagers.
92
 Early recognition of clues to non-compliance, for 
instance wildly variable immunosuppressant levels and erratic lifestyles (including 
school avoidance and irregular sleeping patterns) must be taken seriously, and causes to 
the root problems must be addressed.
93
 Addressing concerns over the cosmetic side 
effects from medication and more convenient medicine regimens may help. 
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Ultimately, psychological and behavioural difficulties must be considered on an 
individual basis. A coordinated multidisciplinary approach to any problems, involving 
medical and nursing teams both at the transplant centre and locally must be undertaken 
where problems arise and include the family doctor, school teachers and nurses, family 
members and teams of specialists such as social workers and special educational 
providers where necessary. 
2.11 OUTCOMES 
There is no doubt that overall outcomes for all age groups following heart 
transplantation have steadily improved over the last thirty years, when large worldwide 
data sets from the International Society of Heart and Lung Transplantation have been 
available (Figure 2.6, Figure 2.7 and Figure 2.8). As useful as these data are, however, 
at producing an overall picture of heart transplant through the world, they are prone to 
the problems inherent in large registries; the patients, medical personnel and protocols 
obviously vary greatly between institutions and countries, and subtle improvements may 
well be masked, and lost in the fog of heterogeneity that is present. 
 
 
 
Figure 2.6 ISHLT registry data displaying post-transplant survival in recipients aged <1 year, over 
three eras. 
Chapter 2  Paediatric heart failure & transplantation 
 49 
 
Figure 2.7 ISHLT registry data displaying post-transplant survival in recipients aged 1-10 years, 
over three eras. 
 
 
Figure 2.8 ISHLT registry data displaying post-transplant survival in recipients aged 11-17 years, 
over three eras. 
 
Certainly, it was with that ethos in mind that this thesis was designed. The overall 
feeling at Great Ormond Street was that our heart transplant protocols were based on 
good theories, but we needed to back up those ideas with solid, local research. For 
instance, the accepted thinking on transplantation for congenital heart disease is that 
outcome is worse than those patients with an original diagnosis of cardiomyopathy 
(Figure 2.9), but with at least anecdotally good success with some children with difficult 
anatomy, I wondered whether with our increasing expertise, outlook for these patients 
was higher than had been previously reported (which became the basis for Chapter 3). 
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Similar questions arose with regards to the use of induction immunosuppression and 
extra-corporeal life support post-transplant, as well as the side-effects of transplant 
medications and effects of CMV post-transplant; those questions are revealed in the 
later chapters. 
 
 
 
Figure 2.9 ISHLT registry data displaying post-transplant survival in recipients transplanted from 
2000-2010 with an original diagnosis of cardiomyopathy vs. congenital heart disease. 
 
 CHAPTER 3 
HEART TRANSPLANTATION FOR CONGENITAL 
HEART DISEASE 
 
With growing numbers of children with complex congenital heart disease surviving 
initial surgical procedures, more patients are presenting in later childhood or early 
adulthood in cardiac failure. This presents an obvious increased burden on transplant 
centres, and a further strain on a limited donor pool. Historically, results for heart 
transplant following congenital heart disease (CHD) have been worse than those 
following cardiomyopathy (CM). With increased surgical experience and intensive care 
expertise, the gap between the two aetiologies in our practice is decreasing. This 
chapter reviews the current protocols for transplantation in this setting, presenting a 
large single-centre experience over 20 years, and speculates on possible future 
advancements in this very challenging field. 
. 
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3.1 INTRODUCTION 
Historically, transplantation for congenital heart disease (CHD) has had a worse 
prognosis than that for heart failure of other aetiologies.
94
 It has been estimated that 
between 10 and 20% of children with complex CHD will at some stage require 
transplantation; since it accounts for approximately 25% of all heart transplants in the 
paediatric age group
95
 – and, with more and more children with CHD reaching 
adulthood, a growing number of early adult transplants – it is important to strive to 
redress this imbalance. Over the 40-year history of heart transplantation, various 
improvements in pre-operative, operative and post-operative care have dramatically 
improved the immediate and long-term outlook for all transplant recipients. 
Furthermore, a number of adaptations specific to congenital heart disease recipients 
have combined to shrink the gap between transplantation for CHD and other 
indications, and patients transplanted for CHD can now reasonably expect to live for a 
decade or more. However, CHD remains a highly significant risk factor for one-year 
and five-year mortality in transplant recipients,
95, 96
 and the wide diversity of this group 
with respect to age, original diagnosis, previous operations and clinical status makes it 
very difficult to analyse accurately different practices or produce clear formal protocols. 
This chapter was designed to study the evolution and outcomes for transplantation for 
CHD in a single centre over almost two decades, and speculates on future advancements 
in this very challenging field. 
3.2 METHODS 
3.2.1 Study population and design 
The notes of the first 259 patients undergoing heart transplant at Great Ormond Street 
Hospital from the beginning of the programme were reviewed. Only first 
transplantations were included, excluding 9 re-transplants. A total of 250 first 
transplants were studied, of which 73 were for CHD (29.4%). The initial diagnoses of 
the CHD group are displayed in Table 3.1. In addition, one patient – whose initial 
diagnosis was tricuspid atresia with VSD – was re-transplanted 3.6 years after her initial 
transplant for failing graft. She is currently well, 13.9 years after her second transplant. 
Only her first transplant is used for this analysis.  
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Biventricular (35) Univentricular (38) 
TGA 12 HLHS 14 
Aortic disease 7 DOV 8 
Mitral disease 4 DIV 6 
Septal defects 4 HRV/PA/TA 10 
Tetralogy of Fallot 4 
ccTGA 2 
Ebstein's anomaly 2 
 
Table 3.1 Diagnoses of 73 patients transplanted for congenital heart disease. TGA – transposition of 
the great arteries; ccTGA – congenitally corrected transposition of the great arteries; HLHS – hypoplastic 
left heart syndrome; DOV – double outlet ventricle; DIV – double inlet ventricle; HRV hypoplastic right 
ventricle; PA – pulmonary atresia; TA – tricuspid atresia. 
 
Transplant management has evolved over the years: for clarity, the initial analysis 
divided the entire cohort chronologically into five groups of fifty transplants. The 
relatively small numbers of patients with congenital heart disease required that for 
meaningful secondary analysis aimed to further probe the success of transplant for 
congenital heart disease (TxCHD), the entire cohort was re-divided into two eras - the 
Millennium was chosen as an arbitrary time point that created two almost equal groups 
of TxCHD patients: 38 transplants were performed prior to 2000, and 35 since. 
3.2.2 Statistical analysis 
The entire data set was used for all statistical analyses. Data were analysed with SPSS 
14.1 for Windows (SPSS Inc.). ―Survival‖ refers to graft and patient survival: censoring 
for the purpose of survival curves was taken at the date of death or re-transplantation, 
whichever came first. The Kaplan-Meier method was used to analyse survival, and 
Wilcoxon tests were used for comparison between groups. 
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3.3 RESULTS 
3.3.1 Survival of entire cohort 
Figure 3.1 displays a Kaplan-Meier curve of survival for the entire cohort of patients 
following first heart transplantation at Great Ormond Street. Survival over this twenty-
year period was 90.8% at 30 days, 86.4% at one year, 73.9% at 5 years, and 59.5% at 10 
years.  
 
Figure 3.1 Kaplan-Meier curve depicting overall survival of entire cohort of 250 patients. 
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3.3.2 Survival by Era 
By dividing the cohort into groups of fifty transplants, the Kaplan-Meier graph shown 
in Figure 3.2 illustrates that overall survival following transplantation has improved 
steadily from the beginning of the programme (Log Rank (Mantel-Cox) p = 0.004)). 
Importantly, the most obvious improvement occurs within the first year, with 30-day 
and one-year survival improving consistently through the groups (Table 3.2). After the 
first year, the slope of each of the curves is largely parallel, indicating little difference in 
long-term outcome conditional on survival to one year post-transplant.  
 
 
Figure 3.2 Survival of the entire cohort, divided into chronological groups of 50 transplants. 
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Transplant number 30-day survival (%) 1-year survival (%) 
1-50 78.0 74.0 
51-100 87.8 81.7 
101-150 96.0 87.8 
151-200 98.0 90.0 
201-250 98.0 98.0 
 
Table 3.2 30-day and 1-year survival grouped chronologically for the entire cohort. 
 
3.3.3 Cardiomyopathy vs. Congenital Heart Disease 
Figure 3.3, Figure 3.4 and Figure 3.5 display survival curves of transplantation for CM 
and CHD divided by the Millennium. 1-year survival for TxCHD improved from 66% 
pre-2000 to 90% post-2000 (p = 0.005). Prior to 2000, 1-year survival for TxCHD was 
significantly worse than that of transplant for cardiomyopathy (TxCM) (66% vs. 84%, p 
= 0.036). There was no such difference in 1-year survival for TxCHD compared to 
TxCM in the post-Millennium era (90% vs. 94%, p = 0.76). 
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Figure 3.3 Survival following heart transplantation for congenital heart disease. Improving results 
post-Millennium. 
 
Figure 3.4 Survival following heart transplantation prior to the Millennium. There is a better outlook 
for patients transplanted for cardiomyopathy than those transplanted for congenital heart disease. 
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Figure 3.5 Survival following heart transplantation post-Millennium. There is no difference between 
cardiomyopathy and congenital heart disease patients. 
3.3.4 Survival post-TxCHD based on original diagnosis 
Figure 3.6 displays survival curves based on univentricular (n = 38) versus biventricular 
(n = 35) circulations. 1-year post-transplant survival for patients with originally 
univentricular circulations was similar to those with originally biventricular hearts (75% 
vs. 78%). 8 of 38 univentricular (21%) and 5 of 35 biventricular (14%) patients died 
within the first 30 days post-transplant (p = 0.45).  
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Figure 3.6 Survival following heart transplantation for congenital heart disease, univentricular vs. 
biventricular anatomies. 
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3.3.5 Survival post-TxCHD in patients with univentricular circulations based on 
Fontan repair stage 
Table 3.3 illustrates the repair stage of those patients with univentricular circulations at 
the time of their transplant. Of the univentricular deaths there were 5/15 Fontans, 1/13 
Glenns, 4/8 Norwoods (Figure 3.7; p = 0.052). Both patients transplanted as a primary 
therapy for a univentricular circulation (i.e. with no prior operation), died in the early 
post-operative period. 
 
Repair Stage n 
No prior operation 2 
Norwood Stage 1 8 
Glenn 13 
Fontan 15 
 
Table 3.3 Repair stage at transplantation of patients with univentricular anatomies. 
 
 
Figure 3.7 Survival of patients with univentricular circulations post-heart transplant. 
 
Chapter 3 Heart transplantation for congenital heart disease 
 61 
Since 2001, Great Ormond Street has also been using mechanical support as a bridge to 
transplant in children, with either extra corporeal membranous oxygenation (ECMO) or 
Berlin Heart. Although we have successfully used these techniques in many patients 
with cardiomyopathy, our experience with mechanical support in TxCHD remains 
limited to two patients. One was a 6 year-old boy with a diagnosis of double inlet left 
ventricle who had had a total cavo-pulmonary connection performed; the other was a 13 
year-old girl who had previously undergone mitral valve repair. Unfortunately, both 
patients died within 10 days of their operation.  
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3.4 CONCLUSION 
This chapter presents the results of a single-centre paediatric heart transplant 
programme over a period of 20 years. These data are reassuring for several reasons. 
Firstly, they show that results of heart transplantation at Great Ormond Street have 
improved steadily from the early operations performed at the end of the late 1980‘s. and 
indicate that the historically high early attrition for transplant for congenital heart 
disease is no longer present.
94
 In addition, transplantation in patients with a failing 
univentricular circulation was not a survival risk factor in our cohort (Figure 3.6). 
 
There can be little doubt that results for transplantation in the setting of CHD have 
improved significantly over the last forty years, and, with many of the difficulties 
involved in this situation now at least partially remediable, the outlook for these patients 
is encouraging, similar to that of patients transplanted for dilated cardiomyopathy.
97
  
 
Heart transplantation is a complex procedure that requires delicate and insightful 
understanding of the processes involved in listing for transplantation, preservation of 
recipient cardiac (and other organ) function, effective use of an increasingly strained 
donor organ pool, skilful operations, dedicated post-operative intensive care, and careful 
long-term medical management to prolong graft function. Many of these problems are 
common to all heart transplantation scenarios, but some are made even more difficult in 
the CHD population. 
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3.4.1 Pre-transplant assessment and listing for transplantation 
With demand for donor organs at a premium, and the life of a transplanted graft being 
limited to approximately 15 years on average, the timing of listing for transplantation 
must be carefully considered, and cannot be premature. However, prolongation of native 
cardiovascular function may come at the price of other cardiac operations, and 
potentially additional organ failure, either of which may be detrimental to the success of 
future transplantation. For instance, post-transplant survival for children with a native 
single ventricle morphology has previously been shown to be related to pre-transplant 
operative stage, and some authors have suggested that listing for transplant with a Glenn 
shunt in situ rather than proceeding to a sub-optimal Fontan circulation may decrease 
the formation of lymphocytotoxic antibodies, restrict worsening pulmonary vascular 
resistance, and limit post-transplant complications such as diastolic dysfunction and 
protein-losing enteropathy, resulting in an overall longer, better quality life.
98-101
 With 
improving long-term outlook for transplant recipients, these arguments hold even more 
influence. Although the numbers are small, the data in this chapter reaffirm that 
transplantation following the Glenn operation, but before completion of a Fontan 
circulation seems to be compatible with the best outlook, with no early or medium term 
deaths. 
 
Paradoxically, given the increased importance associated with accurate listing for 
transplant for CHD, patients are often harder to assess. Specifically, it is important to 
measure pulmonary vascular resistance (PVR) to avoid the potential of donor right heart 
failure.
101
 At Great Ormond Street, a PVR of ≤ 6 Woods units.m2 (or transpulmonary 
gradient (TPG) ≤ 10mmHg) is considered compatible with a good result post-transplant. 
A PVR of 7-16 Woods units.m
2
 (TPG 10-20 mmHg) is potentially more difficult, and 
requires pre-operative vasodilator testing with prostacyclin or nitric oxide, with the 
following inferences: 
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 PVR ≤ 5 Woods units.m2 (TPG ≤ 10 mmHg) – proceed to transplant 
 PVR 5-9 Woods units.m2 (TPG 10-15 mmHg) – transplantation may convey 
increased risk 
 PVR ≥ 9 Woods units.m2 (TPG ≥ 15 mmHg) – heart transplantation 
contraindicated 
 
However, PVR can be hard to estimate in the Fontan circuit, particularly when there is a 
fenestration and extensive venous collaterals. If problems with pulmonary vascular 
resistance are probable, it is wise to avoid undersized hearts and long ischaemic times 
during the operation.
101
 Despite these precautions, post-transplant pulmonary 
vasodilatation with phosphodiesterase inhibitors, nitric oxide or prostacyclin may be 
required, as well as – in extreme cases of right ventricular dysfunction – mechanical 
assistance.
102
 
 
3.4.2 Operative differences 
 
Over the evolution of heart transplantation, the donor and recipient cardiectomy and 
implantation procedures have become largely standardised. However, specific 
anatomical abnormalities in the recipient with CHD – such as vascular and cardiac size, 
position and situs – can necessitate modification of each component. Previously, the 
most complex anatomies would themselves have contraindicated transplantation, 
despite an individual clinical scenario that would otherwise have been compatible with a 
successful operation. Surgical ingenuity has largely overcome anatomical 
contraindications to heart transplant,
103-106
 with the possible exceptions of severe 
pulmonary artery hypoplasia and pulmonary vein stenosis. Crucially, each procedure 
must be appropriately adapted when considering a recipient with CHD. 
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With respect to the donor cardiectomy, it is advisable to harvest extended portions of 
the systemic veins, pulmonary arteries and aorta (in order to facilitate potentially 
complex anastomoses), and graft trimming should be postponed until implantation. 
Judicious retrieval may limit the need for additional prosthetic material in heart 
transplantation, but can hamper transplantation of other organs, notably the lungs. The 
superior and inferior venae cavae can be opened so as to produce a larger right atrial 
opening in small recipients, and the donor PA can be split open to enable connection 
with the distorted or undersized recipient pulmonary vasculature. 
 
Dense pericardial and mediastinal adhesions with marked cardiomegaly in those 
recipients having undergone previous sternotomy can increase the chance of substantial 
haemorrhage. In addition, the presence of substernal great vessels and conduits may 
warrant exposure of the femoral vessels prior to sternotomy as a precautionary measure, 
permitting immediate femoro-femoral cardiopulmonary bypass in emergency 
situations.
97
 In addition, chronically cyanotic patients may have developed collateral 
vessels which can be troublesome, especially in the posterior mediastinum.
107
 It is also 
prudent actively to achieve haemostasis prior to implantation of the donor organ. 
 
Pre-implantation, it may be necessary to re-establish normal recipient anatomy with, for 
instance, a left SVC/innominate vein reconstruction, in the case of bilateral 
cavopulmonary anastomoses. A case of situs inversus requires a spatial rearrangement 
of the systemic venous drainage, by the formation of a bicaval connection using the 
donor innominate vein and left-sided SVC;
108
 it is also useful to open the left pleural 
space to accommodate the normally sited donor organ. These extra elements to the 
operation must be anticipated and corrected for in order to synchronise the donor and 
recipient components of transplantation, and avoid prolonging ischaemic times. 
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3.4.3 Post-operative complications 
Post-operatively, CHD transplant recipients face the complications common to all heart 
transplants of, for instance, multi-organ failure, rejection, infection, coronary allograft 
vasculopathy, and – in the paediatric age group especially – non-compliance.92 
However, specific issues are more problematic in CHD patients. Higher rates of post-
operative bleeding, infection and wound dehiscence in those having undergone previous 
thoracic procedures have been predicted, and, although studies have reported differing 
relative risks for this population,
97, 98, 109
 they must be foreseen in this group. Years of 
sub-optimal end-organ perfusion also increase the chances of significant post-operative 
renal failure; the limited experience at Great Ormond Street of extracorporeal support as 
a bridge to transplant has suggested that this may optimise end organ function, in the 
immediate post-transplant phase at least. The effect this has on later function is 
currently unknown.
 
3.4.4 Lymphocytotoxic antibodies 
The formation of lymphocytotoxic antibodies in response to repeated blood 
transfusion
110
 or homograft tissue
111
 in previous procedures is of particular relevance in 
the CHD group, and has been linked to increased rejection and worse actuarial survival 
post-transplant.
112
 If feasible, it is important to limit pre-sensitization by restricting 
blood transfusion and homograft use
97
 in patients with CHD. Various pre- and post-
transplant protective measures, such as immunoglobulins, cytolitics, plasmapheresis, 
cyclophosphamide and rituximab have been attempted in the event of pre-sensitised 
patients, with varying success.
81, 83, 84
 Again, with more transplants being performed on 
patients with multiple previous operations, this is likely to be a problem that increases 
over the coming years, and one that needs to be addressed actively. 
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It is also vital to recognise that a significant proportion of children with CHD will go on 
to need a transplant after they have been discharged into the care of adult cardiology 
services. However, it is not uncommon for adults with congenital heart disease with 
heart failure or a failing Fontan circulation to not be listed for transplant. This may be 
for a variety of reasons including abnormal renal function, sensitization to HLA 
antibodies, multiple previous surgical procedures, and complex anatomy requiring 
extensive repair. Careful surveillance of other organ function during childhood years, 
avoidance of liberal use of blood products and homograft tissue (with the potential 
adverse effects of immune modulation) and the availability of surgical experience with 
complex anatomical repair may ameliorate some of the problems.  
 
Transplantation saves lives and improves the quality of life for many recipients. The 
gap between the number of organs needed and the supply of donors needs to be 
addressed. However, the lack of adult cardiac transplant centres with congenital 
experience on site remains a practical issue.  
3.5 SUMMARY 
Despite the problems associated with taking more marginal donors, and operating on 
more chronically and acutely sick patients, this chapter illustrates that the immediate 
and long-term outcomes for transplantation for congenital heart disease continue to 
improve. Noticeably, the historical discrepancy between prognosis following 
transplantation for CHD and cardiomyopathy is diminishing convincingly. This success 
is the result of specific advances in the understanding and management of CHD and 
heart transplantation, and the implementation of these by dedicated surgical, medical 
and intensive care teams. However, the heterogeneity of this population – even within 
sub-groups defined by original diagnosis or operative stage – makes it very difficult to 
perform robust longitudinal studies capable of identifying predictive factors for survival 
and improving allocation of scarce resources.  
 CHAPTER 4 
PRE-IMPLANTATION BASILIXIMAB AS 
INDUCTION IMMUNOSUPPRESSION IN 
PAEDIATRIC HEART TRANSPLANTATION 
 
 
Basiliximab is an anti-CD25 monoclonal antibody used as induction therapy in solid-
organ transplantation. This chapter aims to determine whether basiliximab is beneficial 
in preventing early heart allograft rejection, and also if administration prior to 
cardiopulmonary bypass has additional protective effects. The effect of pre-
implantation basiliximab on CD25 count and on acute rejection in children undergoing 
cardiothoracic transplantation is assessed. The notes of all children undergoing 
cardiothoracic transplantation at Great Ormond Street Hospital between January 2000 
and June 2007 were retrospectively reviewed. 121 heart transplant recipients were 
included: 29 patients did not receive basiliximab; 33 patients received basiliximab after 
coming off cardiopulmonary bypass (CPB); and 59 patients received basiliximab prior 
to organ implantation. All patients receiving basiliximab had an effectively suppressed 
CD25 count (< 0.2%) on Days 1 and 10 post-transplant. Freedom from Grade 3A or 
greater rejection in the first year was significantly greater in the pre-implantation 
basiliximab group than in the post-implantation and no-basiliximab groups (95%, 70% 
and 72%, respectively; p = 0.02). Induction regimen was the only significant 
explanatory variable after multivariate Cox regression. The results of this chapter 
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confirm that basiliximab is effective at suppressing CD25 count whether given pre- or 
post-CPB. Basiliximab before transplantation appeared to reduce acute rejection, 
whereas post-CPB administration did not suggest similar effects. These findings would 
benefit from independent validation in randomised trials and further studies should seek 
to mechanistically delineate these observations. 
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4.1 INTRODUCTION 
Anti-lymphocyte induction has been used in cardiothoracic transplantation for more 
than 20 years, with demonstrated safety, efficacy and reduction in the incidence of acute 
rejection episodes in heart
113
 and other solid-organ transplantation.
114, 115
 At many 
centres, children undergoing cardiothoracic transplantation currently receive either anti-
thymocyte globulin (ATG),
116
 or an interleukin-2 receptor antagonist (IL-2Ra), such as 
basiliximab.
117
 The more specific immunosuppressive action of basiliximab has resulted 
in reduced rates of infectious deaths and post-transplant lymphoma compared with 
ATG, but studies aimed at showing a reduction in mortality or rejection have been 
inconclusive.
113, 118-120
 The majority of research in cardiothoracic transplantation has 
investigated a two-dose regimen starting after the recipient has come off 
cardiopulmonary bypass (CPB), due to concerns over wash-out of the drug. 
 
Great Ormond Street Hospital began using basiliximab in 2001, initially utilising a two-
dose regimen on Day 0 (coming off bypass) and Day 4 post-operatively. In 2002, the 
protocol was changed on the basis that it was unlikely that a monoclonal antibody 
would be washed out by CPB, and because it is given before implantation in other solid-
organ transplantation. After this change, the first dose would be given after 
confirmation of the donor organ immediately before the patient went on CPB. 
 
The purpose of this chapter was to ascertain whether timing of basiliximab 
administration determines efficacy of CD25 suppression, or influences the incidence of 
acute rejection. 
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4.2 METHODS 
4.2.1 Patients and Treatment Protocol 
The notes of all children undergoing cardiac transplantation (n = 142) at Great Ormond 
Street Hospital (GOS) between January 2000 and September 2007 were reviewed with 
regards to CD25 count, post-operative infection, allograft rejection and mortality. At 
GOS, CD25 counts were measured on the first day post-transplant and thereafter weekly 
until discharge. 
 
Exclusion criteria included insufficient data on drug administration (n = 9), insufficient 
CD25 count data (n = 1), insufficient biopsy data (n = 4), previous solid-organ 
transplantation (n = 2), metabolic disease (n = 2) and death or graft failure within 24 
hours of transplantation (n = 3). In total, 121 children undergoing cardiac 
transplantation were included, divided into three groups by transplantation era: 
 
1. Children who did not receive basiliximab (n = 29). 14 of these patients receive 
anti-thymocyte globulin. Analysis of these patients showed no difference in 
outcomes compared to patients with no induction therapy; they were therefore 
considered as one group to aid statistical testing. 
2. Children who received the first dose of basiliximab after coming off CPB (n = 
33). 
3. Children who received the first dose of basiliximab prior to organ implantation 
(n = 59). 
 
Those patients given basiliximab received a second dose on Day 4 post-operatively. All 
patients received primary immunosuppression (ciclosporin, tacrolimus or sirolimus), an 
anti-proliferative agent (mycophenolate mofetil [MMF] or azathioprine) and 
prednisolone. These changes were made at the institutional level and saw tacrolimus 
replace ciclosporin and MMF replace azathioprine because of better side-effect profiles. 
Sirolimus was used as primary immunosuppression when there were concerns over 
severe renal impairment. All patients transplanted after 2002 underwent a standard 
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biopsy schedule of 3 biopsies in the first 6 months, regardless of clinical status, with 
subsequent biopsies only if clinically indicated or to follow up rejection.
121
 
4.2.2 Study Outcome Measures 
The primary end-points were CD25 counts on days 1 and 10 post-surgery and freedom 
from acute graft rejection, defined as Grade ≥ 3A. When biopsy was contraindicated 
due to clinical instability, a clinical diagnosis was also counted. Secondary end-points 
were culture-positive infection in the first month after surgery, defined as any positive 
blood, respiratory tract, or urine culture, incidence of post-transplant 
lymphoproliferative disease (PTLD) and all-cause mortality. 
4.2.3 Statistical Analysis 
The full analysis set was used for all statistical analyses. Demographic and baseline 
characteristics were compared using 1-way analyses of variance (ANOVAs) for 
continuous data, and chi-square tests for categorical data. The primary outcome measure 
was analysed using Kaplan–Meier curves and the log-rank (Mantel–Cox) test. Of the 
secondary outcome measures, PTLD and infections were analysed using chi-square 
tests, and all-cause mortality was investigated using Kaplan–Meier curves. The possible 
effects of confounding variables (recipient age at transplant, donor-recipient 
cytomegalovirus mismatch status, primary immunosuppression received, anti-
proliferative agent received) on freedom from graft rejection and on mortality were 
analysed using multivariate Cox regression analyses. The data set was right-censored 
for all survival analyses. All analyses were performed using SPSS, version 14.0 for 
Windows (SPSS, Inc., Chicago, IL). 
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4.3 RESULTS 
4.3.1  Demographics and Baseline Characteristics 
Demographics and baseline characteristics are displayed in Table 4.1. Two independent 
variables differed significantly between the groups: mean recipient age at 
transplantation and recipient cytomegalovirus (CMV) status. In light of evidence that 
the effect of recipient age is non-linear,
67
 this variable was also analysed categorically 
with children divided into infants < 12 months of age and others; this was not 
significantly different between the groups. Both primary immunosuppression and anti-
proliferative drug usage differed significantly by induction regimen, with tacrolimus use 
comparable in those children receiving post-operative (85%) and pre-operative (91%) 
basiliximab, but lower in those not receiving the drug (31%), and MMF use much 
higher in those receiving pre-operative (84%) than post-operative (21%) or no (7%) 
basiliximab. Mean follow-up was 40.7 ± 27.6 months. 
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 No basiliximab 
(n = 29) 
Post-operative 
basiliximab (n = 33) 
Pre-implantation 
basiliximab (n = 59) p 
Recipient characteristics 
Mean age ± SD 
(years) 
10.8 ± 5.5 8.8 ± 6.0 6.9 ± 5.5 0.01 
Infants < 1 year (%) 4 (14%) 2 (6%) 9 (15%) 0.42 
Male % 48 36 48 0.53 
CHD:CM % 24:76 18:82 31:69 0.42 
% CMV positive:  
negative: unknown  
52:41:7 33:64:3 24:76:0 0.02 
Donor characteristics 
Mean age±SD 
(years) 
16.9 ± 10.8 18.3 ± 14.5 16.3 ± 14.2 0.78 
Male % 52% 49% 39% 0.77 
CMV D+/R- % 15% 14% 20% 0.50 
ABO mismatch % 0% 12% 15% 0.09 
 
Table 4.1 Demographics and Baseline Characteristics. CHD – congenital heart disease; CM – 
cardiomyopathy; CMV – cytomegalovirus; CMV D+/R- – CMV donor IgG positive/recipient IgG 
negative. 
 
4.3.2 CD25 Counts 
All patients receiving basiliximab had a CD25 count of < 0.2% within the first 24 hours 
and for at least 10 days post-transplant, indicating effective early T-lymphocyte 
suppression. 
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4.3.3 Acute Rejection 
Overall freedom from acute rejection within 12 months of surgery was 76% in the no-
basiliximab group (22 of 29 children), 76% in the post-implantation basiliximab group 
(25 of 33 children) and 95% in the pre-implantation basiliximab group (56 of 59 
children), which indicated a significant difference between the groups (log-rank test, p = 
0.016). Induction regimen was the only significant explanatory variable (p = 0.023, 
Exp(B) 0.367, 95% confidence interval 0.154-0.873) after Cox regression analysis, 
controlling for the effects of possible confounding variables (chi-square 16.4, p = 0.021 
for model). 
 
There were 4 episodes of early acute rejection between 5 and 10 weeks post-transplant 
in our sample: 1 of these patients received ATG and 3 received pre-operative 
basiliximab. The only child of the 4 who received MMF also received sirolimus. 
 
Extending the analysis to the entire follow-up period gave rates of freedom from acute 
rejection of 72% in the no-basiliximab group (21 of 29 children, mean follow-up 68.9 ± 
25.2 months), 70% in the post-implantation basiliximab group (23 of 33 children, 50.4 ± 
18.8 months) and 95% in the pre-implantation basiliximab group (56 of 59 children, 
21.4 ± 15.3 months). This indicated a significant difference between groups (log-rank 
test, p = 0.01), as shown by Kaplan–Meier estimates (Figure 4.1). Multivariate Cox 
regression was performed as before. The final model was significant (chi-square 17.6, p 
= 0.02) and induction regimen was the only significant explanatory variable (pre-
implantation basiliximab vs. no basiliximab: hazard ratio 7.3 [95% confidence interval 
1.2-45.5]; pre-implantation basiliximab vs. post-implantation basiliximab: hazard ratio 
5.4 [95% confidence interval 1.0-26.1]). 
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Figure 4.1 Kaplan–Meier survival curve showing freedom from acute rejection of Grade 3A or 
worse by induction regimen. Children who received pre-operative basiliximab were more likely to be 
free from acute rejection both within the 12 month pre-transplant and throughout the entire follow-up 
period when compared with children who received post-operative basiliximab or who did not receive 
basiliximab. These latter two groups had very similar rejection profiles at both 12 months and throughout 
the entire follow-up period. 
 
4.3.4 Secondary End-points 
There was no significant difference in culture-positive infections in the first 2 months 
between the groups (14%, 12% and 15%; log-rank, p = 0.92), nor in all-cause mortality 
rates (21%, 9% and 3%; log-rank, p = 0.24) (Figure 4.2). One child who received post-
operative basiliximab developed PTLD 19 months post-transplant. 
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Figure 4.2 Kaplan-Meier curve showing all-cause mortality by induction regimen.  
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In light of the differences in other immunosuppressants received, as well as including 
primary immunosuppression and anti-proliferative type as variables in the main 
analysis, separate univariate analyses were constructed and showed no significant effect 
on rejection within the first year for primary immunosuppression (log-rank, p = 0.12) 
nor anti-proliferative agent (log-rank, p = 0.19). Neither had a significant effect over the 
whole follow-up period (primary immunosuppression: log-rank, p = 0.31; anti-
proliferative agent: log-rank, p = 0.12). Analyses of binary groups comparing 
tacrolimus to any other agent (ciclosporin or sirolimus), and MMF to any other agent 
(azathioprine or nothing) were similarly not significant. Given the particular evidence 
for MMF, Kaplan–Meier curves illustrating rates of rejection among children who did 
and did not receive MMF were constructed for subgroups of children. The data suggest 
that children receiving postoperative basiliximab had slightly higher rates of acute 
rejection with MMF, and those receiving pre-operative basiliximab had slightly lower 
rates, but log-rank tests were non-significant in both cases. We also obtained data on 
calcineurin levels for the majority (n = 106, 87.6%) of children, but these are trough 
levels used to guide dosage rather than an indicator of level of immunosuppression. 
Calcineurin levels were nonetheless not significant on univariate analysis. 
4.4 DISCUSSION 
This chapter has demonstrated that basiliximab is effective at suppressing CD25 counts 
after paediatric heart transplantation, regardless of whether it is given before or after 
CPB. It further suggests that basiliximab is more effective at reducing rates of rejection 
if given before implantation. 
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In cardiothoracic transplantation, basiliximab is frequently given when coming off 
bypass due to concerns over ―wash-out‖ of the drug during CPB, although the original 
research looking at basiliximab used a preoperative dose,
122
 and the manufacturer, U.S. 
Food and Drug Administration (FDA) and British National Formulary (BNF) all advise 
giving the first dose pre-operatively. The CD25 results in our sample allay these 
concerns over wash-out, with all patients having a CD25 count of < 0.2% on the first 
day post-operatively, and none showing a rise in CD25 before day 10. It is of interest to 
note that there are data in renal transplantation suggesting that a single pre-operative 
dose is as effective as a two-dose protocol.
123
 
 
The exact mechanism of basiliximab is unclear. It is a high-affinity chimeric 
monoclonal antibody that is a selective competitive antagonist to the alpha-chain 
(CD25) of the interleukin-2 receptor, which is present only on activated T-lymphocytes 
(IL-2Ra);
122
 it may also reduce activation of T-lymphocytes. By preventing replication 
it reduces activation of B cells and thus inhibits antibody production. Basiliximab 
therefore avoids the broad cross-reactivity seen with older immunosuppressants such as 
ATG, and this selectivity appears to result in a reduced incidence of post-operative 
infections and infectious deaths,
119
 and of post-transplant lymphoma;
124
 it may also 
decrease rejection rates in critically ill children in whom calcineurin inhibitors cannot be 
used in normal doses.
125
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Previous studies investigating the use of basiliximab in cardiac transplantation have 
been inconclusive as to its efficacy compared with other agents at preventing clinically 
significant acute rejection,
113, 119, 120
 although most of these studies gave the first dose of 
basiliximab post-operatively. Rates of acute rejection in this data set were markedly 
lower when basiliximab treatment was started before implantation, with the hazard 
ratios from our sample suggesting that children receiving no basiliximab were 7.3-fold 
more likely to undergo rejection during follow-up compared with those receiving the 
drug pre-implantation, and children who received basiliximab post-operatively were 
5.4-fold more likely to undergo rejection. There are no other studies in cardiac 
transplantation in which basiliximab was administered pre-operatively, although there 
are studies in adult kidney
126
 and liver
127
 transplantation that indicated improvement 
compared with placebo when pre-operative basiliximab was given. Interestingly, there 
is evidence from renal transplantation that giving both basiliximab and low-dose ATG 
offers better rejection outcomes than one or the other.
128
 
 
One possible explanation for our results is that pre-operative basiliximab prevents early 
immunologic insult to the donor organ, which would otherwise occur immediately after 
implantation, and there is evidence that activated IL-2 receptors are internalized in 
about 15 minutes.
129
 Post-operative protocols vary, with the majority specifying that the 
first dose of basiliximab should be given on ―Day 0‖ post-transplant, meaning that there 
is a window of opportunity for T-cell replication. It is possible that immunologic 
pathways have time to become activated peri-operatively, and that this process may be 
prevented by a pre-operative decrease in CD25 cells. Other investigators have 
demonstrated an advantage to starting ATG pre-operatively rather than post-operatively 
in renal transplantation,
130
 suggesting any effect may not be specific to basiliximab. 
 
There was a non-significant trend toward lower mortality in the pre-operative 
basiliximab group when compared with the no-basiliximab group, but not when 
compared with post-operative basiliximab, as illustrated in Figure 4.2. Although the 
follow-up in this study was limited, early acute rejection is known to be a risk factor for 
mortality in paediatric heart transplantation,
67
 and longer follow-up of this cohort may 
demonstrate a mortality benefit in the pre-operative group. 
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There was no post-operative increase in infection in the pre-implantation basiliximab 
group, despite the decrease in acute rejection. Although this is a crude surrogate of 
immune function, it suggests that this group was not over-immunosuppressed in the first 
2 months relative to the other drug regimens, which strengthens the argument that the 
explanation for the different rates of rejection lies in an early immunologic event 
prevented by pre-implantation induction. The fact that I did not show an increase in 
lymphoma or infection related death in the ATG group may be due to the relative small 
sample size and limited follow-up period. 
4.4.1 Limitations 
This study is limited by its retrospective nature, which prevented a comparison of pre-
operative basiliximab to pre-operative ATG. The different groups also received a 
variety of other immunosuppressive medications, and other studies have demonstrated 
reduced rates of rejection with newer anti-proliferative agents and cell-cycle inhibitors. 
In this sample, neither primary immunosuppression nor anti-proliferative type was 
predictive of rejection within the three therapeutic groups on univariate analysis, and 
they were not significant in the main (multivariate) Cox regression analyses. However, 
there is evidence from the area of paediatric renal transplantation that co-administration 
of basiliximab and MMF extends the duration of CD25 saturation from 5 to 10 weeks, 
with the majority of acute rejection episodes occurring in this time window,
131
 and only 
1 of the 4 children in this sample who had early acute rejection episodes received MMF. 
There are also no data on pre-operative CD25 levels, and the study is therefore based on 
the assumption that patients had normal CD25 counts prior to transplantation. 
 
Over the 6 years of the study, the average age at which patients were being transplanted 
decreased. However, the effect this had on graft survival was not statistically 
significant, and Cox regression analyses showed the hazard was in any event small 
(hazard ratio 1.08, 95% confidence interval 0.97 to 1.20). 
 
There was one case of severe anaphylaxis in a 14-month-old child given basiliximab 
previously at an aborted transplant—an experience reported previously132 and common 
to other findings in solid-organ transplantation.
133
 This reinforces the importance of 
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delaying basiliximab until it is certain that the donor organ is suitable to avoid the risk 
of sensitization and anaphylaxis at subsequent transplant. 
4.5 SUMMARY 
In conclusion, these results demonstrate that pre-operative administration of basiliximab 
in paediatric cardiothoracic transplantation is feasible and safe, and it is effective at 
reducing CD25 counts despite subsequent CPB. Although the retrospective nature of 
this study necessitates caution in the assessment of rejection, there was a significantly 
lower incidence of acute rejection in cardiac recipients when compared with post-
implantation administration, and this may prove beneficial to the long-term graft 
function of these patients. A randomized, controlled trial is needed to test the hypothesis 
that basiliximab is more effective at reducing episodes of acute rejection when given 
pre-implantation, and to establish whether reductions in acute rejection improve long-
term graft function. 
 CHAPTER 5 
EXTRA-CORPOREAL LIFE SUPPORT AS RESCUE 
THERAPY FOLLOWING PAEDIATRIC HEART 
TRANSPLANTATION 
 
 
Extracorporeal life support (ECLS) is frequently employed following conventional 
cardiac surgery, with proven success. Its use following paediatric heart transplantation, 
however, is less well documented. This chapter reviews ECLS following paediatric 
heart transplantation, to understand better predisposing factors, morbidity and 
mortality connected to ECLS. The notes of all patients at Great Ormond Street Hospital 
undergoing orthotopic heart transplantation from 1999-2009 were reviewed (202 
transplants; age 0.06-17.91 years). Patients were grouped by pre-transplant diagnosis: 
restrictive cardiomyopathy (n = 17), non-restrictive cardiomyopathy (n = 134) and 
anatomical heart disease (n = 51). 28 patients required ECLS post-transplantation 
(13.9%). Those requiring ECLS had a longer ischemic time (4.2 vs. 3.7 hours, p = 
0.02). 35.3% of RCM patients required post-operative ECLS – a significantly higher 
proportion than for DCM (10.4%) or anatomical heart disease (15.7%) (Pearson’s chi-
square 7.99; p = 0.02). On multivariate logistic regression analysis, factors associated 
with post-transplant ECLS were RCM, longer ischemic time and ECMO pre-transplant. 
Graft survival was significantly higher in the non-ECLS group, with a one-year survival 
of 98.2% vs. 57.7% and five-year survival of 84.5% vs. 57.7%. The requirement for 
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ECLS was much higher in this cohort than would be expected for conventional cardiac 
surgery. Although just over one-half of patients requiring ECLS post-transplant 
survived to discharge, they had an excellent medium-term survival, with all still alive. 
ECLS is an expensive, invasive therapy, with significant morbidity and mortality. 
However, without ECLS, it is likely that those patients would have perished. Its 
judicious use, therefore, can be recommended in this setting. 
Chapter 5 ECLS as rescue therapy following paediatric heart transplantation 
 85 
5.1 INTRODUCTION 
Modern improvements in cardiac surgery, intensive care and transplant medicine have 
improved the outcomes for paediatric heart transplant recipients over the last two 
decades.
134
 In addition, conventional cardiac surgical techniques are able to palliate 
children born with congenital heart disease that previously would have not survived 
beyond infancy, a proportion of whom will come to the point where transplantation is 
their only therapeutic option.
135
 Unfortunately, in contrast to this growing pool of 
potential recipients for paediatric heart transplantation, donation rates are relatively 
static.
136
 This imbalance has led to the difficult situation of transplant programmes 
being burdened with a more heterogeneous – and therefore more technically demanding 
– group of transplant candidates waiting for longer on the transplant list (and becoming 
more unwell, with in particular potential for increasing pulmonary vascular resistance 
(PVR)), and being forced to accept donor organs from marginal donors.  
 
The consequence of these shifts in recipient morbidity and donor quality is further strain 
on the critical immediate post-operative period, increasing the possibility of early graft 
failure. To combat this, transplant programmes have increasingly had to rely on 
additional rescue measures, such as nitric oxide and extra-corporeal life support 
(ECLS)
137
 to attempt to support the circulation whilst waiting for a donated graft to 
recover. The indications, risk factors and outcomes of the use of ECLS in this setting 
are not well documented, particularly in the paediatric population. This chapter was 
designed to review the success of ECLS as a rescue therapy post-paediatric heart 
transplantation over the last decade at GOS, and to uncover any risk factors pre-
disposing patients to the need for ECLS. 
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5.2 METHODS 
5.2.1 Study Group 
The study is a retrospective review of all paediatric orthotopic heart transplants at Great 
Ormond Street Hospital over an 11-year period from January 1999 to December 2009 
inclusive, using institutional transplant and ECLS databases. The start of the study 
period reflected the date at which ECLS became a standard treatment option for graft 
failure immediately post-transplant at our hospital. During this period, 202 orthotopic 
transplants were performed (103 female recipients), including 8 re-transplants (age at 
transplantation 0.06-17.9 years (median 9.6 years)); in addition, 2 heterotopic heart 
transplants were conducted – these were not considered for analysis. The group was 
divided based on pre-transplant diagnosis (Figure 5.1): of 151 transplants for 
cardiomyopathy, 17 were for restrictive cardiomyopathy – the RCM group. Dilated (n = 
129) and hypertrophic (n = 5) cardiomyopathies were considered as one – the non-
restrictive cardiomyopathy group (n = 134). The third group was transplants for 
anatomical disease (n = 51, 48 of which were congenital heart disease, and 3 for 
acquired surgical heart disease: two patients with non-congenital valve pathology 
secondary to Marfan‘s disease and one with infective endocarditis).  
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Figure 5.1 Study population divided by pre-transplant diagnosis. RCM – restrictive cardiomyopathy, 
HCM – hypertrophic cardiomyopathy, DCM – dilated cardiomyopathy. Numbers indicate the number of 
patients in each group. Red boxes indicate the final groupings used in analysis.  
 
5.2.2 Local Transplant Protocol 
Pre-transplant work-up involves formal catheter-based PVR measurements for any 
potentially high-risk patients, including those with suspicion of pulmonary hypertension 
on echocardiography, and all patients with restrictive cardiomyopathy. During the study 
period, 25 patients had a ventricular assist device prior to transplantation (all 
cardiomyopathies), and 38 patients had a period of extra-corporeal membranous 
oxygenation (ECMO); 9 patients overlap both groups, in that they had a period of 
ECMO followed by VAD. In total, 54 patients had some sort of mechanical support 
before transplantation.  
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5.2.2.1 Recipient Operation 
Through a median sternotomy, cardiopulmonary bypass is initiated by venous drainage 
via cannulas in the SVC and IVC, and arterial return via an ascending aorta cannula at 
the level of the innominate artery. Body cooling is carried out to 32◦C, unless deeper 
hypothermia is requested for correction of complex heart defects (such as aortic arch 
reconstruction). 
 
The aorta is cross-clamped. The heart is excised by dividing the right and left atrial 
walls close to the atrioventricular groove and the atrial septum, leaving a cuff of atrial 
wall to allow suture of the donor heart. For the bicaval anastomosis technique, the SVC 
and IVC are transected with a rim of atrial tissue on each. The rest of the right atrium is 
excised. The aorta and the main pulmonary artery are divided as close to their respective 
valves as possible. Subsequently, these vessels may be trimmed before being sutured to 
their counterparts of the donor heart. The donor heart is placed over the left side of the 
divided sternum, parallel to the remnant of the excised recipient heart. The donor heart 
is rotated to the left, so that its posterior surface faces anteromedially, such that the free 
walls of both recipient and donor left atria lie adjacent to each other. They are sutured to 
each other, using continuous polypropylene, starting at the base of the left atrial 
appendage of the donor heart and at a point close to the caudal end of the recipient left 
superior pulmonary vein. At a convenient stage, the donor heart is drawn down into the 
pericardium and the suture tightened. The suturing is continued around the superior and 
inferior walls of the left atrium onto the atrial septum. For the bicaval anastomosis, each 
vena cava is anastomosed individually. This technique requires meticulous attention to 
avoid purse-stringing or kinking of the SVC. Because of this risk, right atrial 
anastomosis may be another option of connection in small infants. 
 
Aortic and pulmonary anastomoses are done in standard fashion. The left heart is 
meticulously de-aired and the cross-clamp is removed. Rewarming is started at this 
stage. The caval snares are released and the right heart is also de-aired. Monitoring lines 
are placed in the left atrium and the pulmonary artery. Right atrial and right ventricular 
pacing wires are inserted. When the myocardial function appears satisfactory, the 
patient can be weaned off the cardiopulmonary bypass.  
Chapter 5 ECLS as rescue therapy following paediatric heart transplantation 
 89 
5.2.2.2 Post-operative Care 
Standard early post-operative care included inotropic support with milrinone, and low-
dose epinephrine infusion, if required. Recipients that were suspected of having an 
elevated pulmonary vascular resistance were commenced on inhaled nitric oxide from 
the operating room, and this is weaned off during recovery. In recipients that developed 
renal failure manifested by oligoanuria, fluid overload or electrolyte imbalance, renal 
support in the form of continuous veno-veno hemofiltration was initiated in a timely 
fashion. Where conventional intensive care supports were ineffective and the circulation 
was failing, mechanical circulatory support was commenced, in the majority of cases 
with ECMO via either transthoracic or peripheral cannulation depending on patient 
factors and operator preference. 
 
5.2.2.3 Immunosuppression 
Over the study period, the immunosuppression regime evolved from induction with 
anti-thymocyte globulin to basiliximab, and standard maintenance triple 
immunosuppression from ciclosporin to tacrolimus, and azathioprine to mycophenolate 
mofetil, in addition to prednisolone, which – in the absence of significant rejection – is 
weaned over the first three months. 
 
5.2.3 Study Outcome Measures 
The primary outcome measures were (1) need for ECLS in the early post-transplant 
phase (defined as within 30 days of transplantation), and (2) graft loss, comprising death 
or re-transplantation. Secondary outcome measures were length of intubation, length of 
in-hospital stay, cerebrovascular accident, seizure (clinical or on selective EEG 
monitoring) and laboratory proven infection post-transplant. 
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5.2.4 Statistical Analysis 
All statistical analyses were run using the entire data set, unless stated. The transplants 
were separated into those requiring ECLS immediately post-transplant (―ECLS group‖) 
and those without (―non-ECLS group‖). Demographic and pre-transplant parameters 
were compared using two-sample Wilcoxon rank-sum (Mann-Whitney U) tests for 
continuous data, and Chi-squared tests for categorical. There was a small number of 
missing variables: ischemic time was missing in 2 patients, donor weight (and therefore 
donor:recipient weight ratio) in 4, and hours intubated in 3. Graft survival was analysed 
with Kaplan-Meier curves and the log rank (Mantel-Cox) test. Factors associated with 
the need for post-transplant ECLS were analysed with a multivariable logistic 
regression analysis. A p-value < 0.05 was considered significant. All analyses were 
performed using Stata v.12 (StataCorp LP, Texas, USA). 
5.3 RESULTS 
5.3.1  Need for ECLS 
Of 202 orthotopic heart transplants in this study, 28 (13.9%) resulted in post-transplant 
ECLS; 24 were supported with veno-arterial extra-corporeal membranous oxygenation 
(V-A ECMO) only, 2 with right ventricular assist devices (RVAD) only, and 2 with V-
A ECMO followed by RVAD. Primary indications for ECLS were primarily left 
ventricular failure (n = 2), right ventricular failure (n = 10), biventricular failure (n = 
12), cardiac arrest (n = 2) and arrhythmia (n = 2). Of the 26 patients commenced on V-
A ECMO, 8 had neck cannulation, 2 had neck and femoral cannulation, and 16 were 
cannulated trans-thoracically. A left atrial vent was used in 9. 
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5.3.2 Pre-transplant and Transplant Variables 
Pre-transplant variables are shown in Table 5.1. There was no significant difference 
between the ECLS and non-ECLS groups with respect to age, sex, or VAD pre-
transplantation. Re-transplantation tended to be more common in the ECLS group 
(7.1% vs. 3.4%), but the difference did not reach statistical significance. Patients 
requiring ECLS post-transplant were significantly more likely to have required ECMO 
prior to transplantation (35.7% vs. 16.1%, p = 0.01). 
 
Variable Non ECLS group (n = 174) ECLS group (n = 28) p 
Age (years) 9.6 (0.1 – 17.9) 10.0 (0.7-17.0) 0.65 
Female Sex 97 (55.7%) 14 (50%) 0.57 
ECLS prior to HTx 28 (16.1%) 10 (35.7%) 0.01 
VAD prior to HTx 21 (12.1%) 4 (14.3%) 0.74 
Re-transplant 6 (3.4%) 2 (7.1%) 0.32 
 
Table 5.1 Pre-transplant variables. Continuous variables are given as median followed by range in 
parenthesis unless stated; categorical variables are given as n followed by percentage of each group 
fulfilling the variable in parenthesis. ECLS – extracorporeal life support, VAD – ventricular assist device, 
HTx – heart transplantation. 
 
Transplant variables are displayed in Table 5.2. There was no statistical difference 
between the groups with respect to donor or recipient weight or ratio (as a continuous 
variable), or ABO mismatch. However, it should be noted that patients requiring ECLS 
were more likely to have an extreme donor:recipient weight ratio (i.e. ≥ 3, when 
considering it as a categorical variable). In addition, those patients requiring ECLS post-
transplant had significantly longer median ischemic time (4.15 vs. 3.74 hours, p = 0.02). 
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Variable Non ECLS group (n = 174) ECLS group (n = 28) p 
ABO mismatch 17 (9.8%) 2 (7.1%) 0.69 
Recipient weight (kg) 23.1 (3.1 – 95.5) 30.9 (6.0 – 74.7)  0.27 
Donor weight (kg) 50.0 (2.0 – 90.0) 55.0 (10.0 – 90.0) 0.22 
Donor age (years) 16 (0.3-56) 21 (3-53) 0.08 
D:R weight ratio 1.69 (0.65 – 3.73) 1.65 (0.70 – 4.00) 0.95 
D:R weight ratio ≥ 3 15 (8.6%) 6 (21.4%) 0.04 
Ischemic time (hours)  3.7 (1.1 – 7) 4.2 (1.5 – 8) 0.02 
 
Table 5.2 Transplant variables. ABO mismatch and D:R weight ratio ≥ 3 values are given as n 
(percentage); all other values represent median (range). D:R – Donor:Recipient. 
 
5.3.3 Post-transplant Morbidity 
Those patients receiving ECLS post-transplantation had longer hospital stay, and were 
significantly more likely to require renal replacement therapy (82.1% vs. 22.4%, p < 
0.001), suffer stroke (17.9% vs. 2.3%, p < 0.001) or acquire laboratory proven infection 
(21.4% vs. 2.9%, p = 0.040) prior to hospital discharge (Table 5.3). Two patients were 
re-transplanted directly from ECLS: one died 10 days after her second transplant; the 
second is alive at most recent follow-up, 10 years post-transplant. 
 
Variable Non ECLS group (n = 174) ECLS group (n = 28) p 
Renal replacement therapy 39 (22.4%) 23 (82.1%) < 0.001 
Hospital acquired infection 14 (8.0%) 6 (21.4%) 0.04 
Seizure 5 (2.9%) 1 (3.6%) 0.85 
Cerebrovascular accident 4 (2.3%) 5 (17.9%) < 0.001 
Length of hospital stay (days) 6 (0 – 208) 21 (9 – 55) < 0.001 
 
Table 5.3 Post-transplant morbidity. Length of stay is given as median (range). All other data are n 
followed by (percentage). 
5.3.4 Pre-transplant Diagnosis 
Of 17 transplants undertaken for restrictive cardiomyopathy (RCM) during the study 
duration, 6 (35.3%) required post-operative ECLS (Table 5.4). This proportion was 
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significantly higher than that for dilated cardiomyopathy (DCM) (14 of 134 transplants 
– 10.4%) or anatomical heart disease (8 of 51 transplants – 15.7%) (Pearson‘s Chi-
square = 7.99; p = 0.018).  
 
Diagnosis Non ECLS group ECLS group  
Restrictive Cardiomyopathy (n = 17) 11 (64.7%) 6 (35.3%) 
Non-restrictive cardiomyopathy (n = 134) 120 (89.6%) 14 (10.4%) 
Anatomical heart disease (n = 51) 43 (84.3%) 8 (15.7%) 
 
Table 5.4 Pre-transplant diagnosis groupings. Non-restrictive cardiomyopathy comprises dilated and 
hypertrophic cardiomyopathies; anatomical heart disease covers congenital heart disease and acquired 
valvar disease. 
 
5.3.5 Multivariate Regression Analysis 
On multivariate logistic regression analysis, factors associated with a need for post-
transplant ECLS were RCM (odds ratio 5.12, C.I. 1.47-17.91), longer ischemic time 
(odds ratio 1.53, C.I. 1.05-2.23) and ECMO pre-transplant (odds ratio 3.59, C.I. 1.43-
9.06) (Table 5.5). Although donor:recipient weight ratio as a continuous variable was 
not associated with post-operative ECLS, extreme ratio (taken as ≥ 3) was predictive of 
ECLS post-transplant (odds ratio 4.9, C.I. 1.45 – 16.09). Recipient and donor ages, 
surgical heart disease, and donor cardiac arrest were all non-significant. 
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Variable OR p [95% C.I.] 
ECMO pre-HTx 3.59 0.007 1.43-9.06 
D:R weight ratio  3 4.9 0.009 1.45-16.09 
Ischemic time (min) 1.53 0.03 1.05-2.23 
RCM 5.12 0.01 1.47-17.91 
 
Table 5.5 Multivariate analysis of predicators for post-operative ECLS. D:R – Donor:Recipient; 
RCM – restrictive cardiomyopathy; HTx – heart transplant 
 
Graft survival was significantly higher in the non-ECLS group, with a five-year survival 
of 84.5% (95% C.I. 77.9-90.0%) vs. 57.7% (37.7-73.9%) (Figure 5.2; p = 0.0006 Log 
Rank). The most striking difference in post-transplant mortality was the high early 
attrition seen in the ECLS group, with a thirty-day mortality of 31.7% (16.7-52.2%) vs. 
0%, and one-year mortality of 42.3% (36.1-73.3%) vs. 1.8% (0.6-5.2%). There have 
been no subsequent deaths seen in patients requiring ECLS post-transplant who 
survived to one year. 
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Figure 5.2 Kaplan-Meier curves demonstrating overall survival based on need for ECMO post-
transplant. 
 
5.3.6 Pre-transplant pulmonary vascular resistance data in patients with RCM 
At Great Ormond Street, some patients with clinical concern over their pulmonary 
vascular resistance prior to transplantation undergo cardiac catheterisation in order to 
reduce the chances of a futile transplant. In this group, 12 patients with RCM had PVR 
studies performed prior to transplant, with reversibility of raised pulmonary pressure 
(tested with a combination of increased inspired oxygen fraction and inhaled nitric 
oxide) performed in 8. Of the 12 patients, 5 (41.7%) required ECLS immediately post-
transplant.  
 
Data for transpulmonary gradient and indexed pulmonary vascular resistance were 
analysed with the student‘s t-test, following testing for normality with the Shapiro-Wilk 
test. There was no significant difference between those requiring ECLS post-transplant 
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and those not with regards to TPG or PVRI, either at baseline, or with vasodilator 
testing (see Table 5.6).  
 Non-ECLS RCM (n = 7) ECLS RCM (n = 5) p 
TPG at baseline 
(mmHg) 
10 ± 4.3 17.3 ± 7.9 0.17 
PVRI at baseline 
(Woods.units.m
2
) 
3.9 ± 1.6 3.3 ± 1.5 0.51 
TPG with vasodilation 
(mmHg) 
9.3 ± 1.5 7.0 ± 4.4 0.86 
PVRI with vasodilation 
(Woods.units.m
2
) 
2.6 ± 0.9 2.4 ± 1.2 0.26 
 
Table 5.6 Transpulmonary gradient and indexed pulmonary vascular resistance. Data are presented 
as mean ± SD 
 
As there are published and local thresholds at which TPG and PVRI would a classify a 
transplant as high-risk, they were also analysed at categorical data (with Pearson‘s Chi-
square test), with cut-offs for TPG of 15 mmHg and PVRI of 6 Woods.units.m
2
. All 12 
patients had a PVRI of < 6 Woods.units.m
2
 at baseline and with vasodilation; 3 patients 
had a TPG > 15 mmHg at baseline, but none had TPG > 15 mmHg with vasodilation. 
1/7 patients with baseline TPG < 15 mmHg and 2/5 with baseline TPG >15 mmHg 
required ECLS post-transplant (p = 0.31). 
 
5.4 DISCUSSION 
This chapter reviews the use of ECLS as a rescue therapy following paediatric heart 
transplantation at a single institution over an 11-year period. During that time, ECLS 
was employed 28 times (14% of transplants), with approximately half of the patients 
surviving until 1 year. Conditional medium-term survival in patients surviving the first 
post-transplant year was excellent, with no later deaths in those 15 patients (median 
follow-up 6 years). Factors associated with a need for ECLS post-transplant were 
restrictive cardiomyopathy, pre-transplant ECMO, and longer ischemic time. 
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ECLS is an invasive, expensive therapy that carries with it a significant burden of 
morbidity and mortality, which has been increasingly employed in paediatric cardiac 
centres for over three decades.
138
 In the post-heart-transplant setting, it can be utilized to 
give the donor organ time to recover from the peri-operative insults suffered during 
donor death, explantation and re-implantation, and in certain cases may be the only 
viable option to support a failing heart.
137, 139, 140
 This chapter highlights the significant 
morbidity and mortality associated with its use; it is important to stress however, that in 
each of the 28 cases, conventional means of support had been exhausted, and in the 
absence of mechanical support, the demise of the patient was thought unavoidable. 
 
The indication for ECLS post-treatment was in the majority of cases right ventricular 
failure, with or without concomitant left ventricular failure, a finding which reflects 
previous series.
137, 140-142
 The explanation of this phenomenon is the sudden exposure of 
the donor graft to higher pulmonary vascular resistance (PVR) in the recipient. 
Conventional therapies to lessen the impact of pulmonary hypertension on the donor 
graft including inotropes (e.g. milrinone) and nitric oxide have certainly improved 
survival in such scenarios, and are now considered standard at many institutions, 
including Great Ormond Street;
143
 if high PVR is suspected or known prior to 
transplantation, an atrial communication is created in the donor heart at implantation to 
act as a let-off valve in the case of high right-sided pressures. Prostacyclin, bosentan and 
sildenafil have also been used in this setting.
144, 145
 However, despite these techniques in 
combination, a period of pulmonary hypertension post-transplant is sometimes 
unavoidable.  
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One group of patients considered at a higher risk for early graft loss due to high 
pulmonary pressures is those with restrictive cardiomyopathy,
146
 where the 
development of pre-transplant pulmonary hypertension can be sudden and severe,
147
 and 
may go unnoticed clinically. Furthermore, in the setting of worsening heart failure, it 
may not be discernable with standard echocardiographic measures such as tricuspid 
regurgitation jet velocity. In the course of the transplant programme at Great Ormond 
Street this patient group has proved problematic, with timing of listing for 
transplantation a particular conundrum. Over the 24-year history of transplantation here, 
the protocol has been modified such that all RCM patients have an atrial communication 
created in their donor hearts, and start milrinone and inhaled nitric oxide in theatre. 
However, this work indicates that – even with these measures – over one-third of RCM 
patients still require early mechanical support. The indication for ECLS post-transplant 
in the 6 patients in the RCM group was right ventricular failure in three, biventricular 
failure in two, and left ventricular failure in one. These proportions would be consistent 
with the hypothesis that high PVR immediately post-transplantation is relatively 
common in the RCM group, and has significant impact with graft function. 
 
It is clear that the requirement for ECLS is much higher following transplantation than 
conventional cardiac surgery; at Great Ormond Street, for example, ECLS is required in 
approximately 2% of patients post-cardiac surgery,
148
 as compared to the 14% in the 
current post-transplant data. This difference must be due – at least in part – to the 
operative substrate, with transplant patients often being in a worse clinical state, and 
with a higher rate of previous sternotomies. However, it is likely that the peri-operative 
insults peculiar to transplant surgery, including donor injury, explantation (including 
ischemia) and immunological factors post-implantation are also important factors 
resulting in the increased need for ECLS in this group. 
. 
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The influence of longer ischemic times on paediatric transplantation is a matter of on-
going debate.
134, 149-151
 With the growing imbalance between transplantation lists and 
donor rates, ―marginal donors‖, including those geographically distant to the recipient 
with predictably longer ischaemic times, must be considered. These data suggest that 
those patients requiring ECLS post-transplant had ischemic times on average 30 
minutes longer than those who proceeded without ECLS, a finding that reflects a recent 
paper from Colorado.
141
 Interestingly, long-term outcome was not found to be affected 
by ischemic time in the latest registry figures from the International Society of Heart 
and Lung Transplantation.
134
 In contrast, however, a recent and comprehensive review 
of paediatric transplantation in the U.S. concluded that an ischemic time of more than 
three-and-a-half hours was associated with a 30% increase in early graft loss; 
interestingly, in patients surviving to 6 months, there was no difference.
151
 The 
propensity for those patients in our series receiving ECLS as a rescue therapy to have 
longer ischemic times fit well with those U.S. data, as does the excellent later survival 
in those patients surviving to hospital discharge.  
 
Another consequence of fewer donors and longer waiting times is the increased use of 
mechanical support as a bridge to transplantation. These data indicate that patients on 
ECMO at the time of transplantation were more likely to require rescue ECLS; 
conversely, those receiving transplants after bridging with a ventricular assist device 
were not. One possible explanation for this difference is that those on ECMO pre-
transplant bring with them the highest levels of co-morbidity, whereas a period of 
relative stability on a ventricular assist device may improve the substrate for 
transplantation in those highest risk patients. In particular, improved cardiac output for a 
sustained period with an LVAD may help to reverse pulmonary hypertension,
152, 153
 and 
this effect may have helped avoid the need for post-transplant ECLS in those patients. 
In the setting of limited donor availability, and taking into consideration the substantial 
burden on health care systems of having children on ventricular assist devices, it is 
impossible to justify an ―elective‖ period of LVAD support as a standard treatment if a 
donor organ was available, but it is encouraging that once stabilized, these patients have 
a smoother post-operative course. 
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It was not surprising that the ECLS group suffered a more intense post-operative 
morbidity than those not requiring ELCS, with obviously longer hospital stay. In 
addition, they showed higher rates of renal replacement therapy, infection and stroke. 
The increased requirement for dialysis probably relates at least in part to the period of 
low cardiac output that necessitated ECLS originally, combined with co-existent pre-
renal impairment prior to transplantation. Infection is a common complication of ECLS, 
and for this reason our post-transplant antibiotic prophylaxis in patients on ECLS is 
extended to include antifungal cover and prolonged use of i.v. antibiotics. Despite these 
interventions however, it has not been possible to fully neutralize the increased 
susceptibility to infection of this group, and there were over twice as many laboratory 
proven infections in those on ECLS.  
 
The rate of cerebrovascular accidents in the ECLS group was also predictably higher 
than the non-ECLS group, with 17.9% of patients suffering an event. This figure is 
roughly comparable to both the American ELSO registry figures for cerebrovascular 
events
154
 and a specific post-transplant series from Colorado.
141
  
 
The excellent medium-term survival in the sub-group of patients surviving ECLS post-
transplant to hospital discharge is a potentially interesting finding. This may be nothing 
more than an effect of relatively small numbers, but it might also be hypothesized that a 
period of ECMO in the immediate post-operative phase may in some way protect 
against the high immunological insult that transplanted grafts receive during that time. 
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5.5 SUMMARY 
In summary, these data indicate a good improvement with ECLS in short-term outcome 
for paediatric patients suffering from acute graft failure in the post-transplant phase – 
patients whose prognosis would otherwise be bleak. Encouragingly, survival through a 
period of mechanical support seems to be followed by excellent medium-term 
outcomes. This series indicates that restrictive cardiomyopathy, longer ischemic time 
and pre-transplant ECMO support are risk factors for the need for post-transplant ECLS 
- it is possible that aggressive interventions in the peri-operative phase of such patients 
(including attempts at normalizing high PVR) may further improve their short-term 
outcomes.  
 CHAPTER 6 
TACROLIMUS IN PAEDIATRIC HEART 
TRANSPLANTATION: AMELIORATED SIDE-
EFFECTS IN THE STEROID-FREE, STATIN ERA 
Due to concerns over the side-effects of ciclosporin, tacrolimus is widely used in 
paediatric heart transplantation. However, tacrolimus therapy is also accompanied by 
potentially serious side-effects. This chapter examines the side-effect profile of 
tacrolimus in a large group of paediatric heart recipients. Data on renal function, 
diabetes, hyperlipidaemia and hypertension were collected by case-note review of 100 
patients who had received at least 12 months’ treatment with tacrolimus. 42 patients 
received tacrolimus from the time of transplant (de novo), and 58 were initially treated 
with ciclosporin (switch). Mean estimated glomerular filtration rate improved in the 
first six months post-transplant in the de novo group (66.7 to 84.6 mls/min/1.73m
2
, p = 
0.002). Conversely, it decreased in those initially treated with ciclosporin (82.1 to 68.8, 
p = 0.032), but improved after switch to tacrolimus (77.3 to 85.6, p = 0.006). 21% of 
patients exhibited glucose intolerance, and 2% had diabetes. 4.4% had borderline or 
elevated fasting cholesterol levels. Hypertension was seen in 67% at the point of switch 
from ciclosporin, which fell to 36% at latest follow-up (p = 0.001). These results 
present an encouraging outlook for this cohort of patients. The relatively low levels of 
complications shown may be due to early weaning of steroids, and concomitant statin 
therapy. 
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6.1 INTRODUCTION 
Tacrolimus was first used in paediatric heart transplantation in 1989.
155
 Since then, it 
has widely started to replace ciclosporin as primary immunosuppression, due to 
concerns over the latter‘s side-effects. Tacrolimus is thought to have at least as good 
efficacy as ciclosporin in preventing graft rejection,
156, 157
 thereby prolonging graft 
survival. There remain, however, concerns over tacrolimus‘ own side-effect profile,158 
including renal dysfunction, glucose and lipid abnormalities, and hypertension – all of 
which have particular relevance to heart transplant patients: not only are they prominent 
stimuli for the development of later allograft vascular disease (and therefore risk factors 
for graft loss), but they are all considerations when deciding on suitability for re-
transplantation, when the original graft fails. This study reviews the prevalence of 
unwanted effects in a large group of paediatric heart transplant recipients taking 
tacrolimus. 
6.2 METHODS 
6.2.1 Study Population 
The notes from all heart transplant patients at Great Ormond Street Hospital were 
retrospectively reviewed up until 2006 (n = 226). Only those patients with a follow-up 
whilst receiving tacrolimus for at least one year were included; in the 126 patients 
excluded with a shorter tacrolimus period were six who had died within the first year. 
Included patients (n = 100) were then separated into two groups: those that were started 
on tacrolimus immediately post-transplant (―de novo‖) and those that were switched to 
tacrolimus having previously been on ciclosporin (―switch‖) (Table 6.1). No patients 
have been switched from tacrolimus to ciclosporin at our institution. The local 
immunosuppression regime consists of basiliximab induction, followed by six months 
of weaning prednisolone. An antiproliferative agent (mycophenolate mofetil (MMF) or 
azathioprine) and a calcineurin inhibitor (tacrolimus or ciclosporin) are prescribed in all 
cases). 
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 Switch group De novo group 
Number of patients 58 42 
Male sex (%) 24 (41) 19 (45) 
Median age at transplant 
(years (range)) 
6.6 (0 – 16.0) 10.1 (0.3 – 17.3) 
CM:CHD 44:14 33:9 
 
Table 6.1 Patient characteristics. CM – cardiomyopathy; CHD – congenital heart disease.  
6.2.2 Data collection 
Data were collected from all included patients concerning post-transplant complications 
potentially related to tacrolimus use. Renal function was assessed by collection of serum 
creatinine levels at transplant, six months post-transplant (to assess improvement of 
acute renal failure following normalization of cardiac function) and at latest follow-up. 
In the switch group, creatinine levels at the point of changing from ciclosporin to 
tacrolimus were also recorded. Estimated glomerular filtration rate (eGFR) was 
calculated using the Schwartz formula.
159
 Proportions of children with relative renal 
impairment were calculated according to the National Kidney Foundation guidelines.
160
 
Blood pressure measurements were taken at all follow-up visits, and a 24-hour 
ambulatory blood pressure test was performed on an annual basis. These values are used 
to direct anti-hypertensive treatment, and the requirement for such treatment was used 
for the present analysis. Fasting serum glucose measurements were used to assess post-
transplant glucose intolerance (5.6-6.9 mmol/l) and diabetes (≥ 7 mmol/l),161 and fasting 
cholesterol and triglyceride values used to assess lipid metabolism. A cholesterol of > 
4.4 mmol/l was considered borderline, and a level of > 5.2 mmol/l was considered 
elevated.
162
 Fasting samples were taken at the time of their annual review – a two day 
stay with fasting samples taken whilst fasted for cardiac catheterisation. 
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6.2.3 Statistical Analysis 
Statistical analyses were run using SPSS 14.0 for Windows (SPSS Inc.). Following 
testing for normality using the Kolmogorov-Smirnov test, comparisons involving non-
normally distributed data were performed using the Mann Whitney U test 
(triglycerides); normally distributed data were analysed with paired t-test (renal 
function) or unpaired t-test (cholesterol, glucose). Proportions of patients treated with 
anti-hypertensives, and with elevated glucose or cholesterol levels were analysed using 
Pearson‘s Chi-square test. 
 
6.3 RESULTS 
6.3.1 Renal Function 
In those taking tacrolimus immediately after transplant (de novo), there was an 
improvement in eGFR from transplant to six months later (n = 42, mean 66.7 and 84.6 
mls/min/1.73m
2
, p = 0.002) (Figure 6.1). From 6 months to latest follow-up (mean 1.2 
years), eGFR remained stable (84.6 to 89.6, p = 0.162). Conversely, in those taking 
ciclosporin during the initial post-transplant period (switch), eGFR worsened in the first 
six months from 82.1 to 68.8 (n = 32, p = 0.032), and remained stable (71.1 
mls/min/1.73m
2
) until switch to tacrolimus (mean 3.4 years, p = 0.614). From the point 
of switching from ciclosporin to tacrolimus until latest follow-up (mean 3.0 years), 
eGFR improved (n = 58, mean eGFR 77.3 to 85.6, p = 0.006). 
 
eGFR was also employed to deduce the proportion of patients in different stages of 
renal impairment at latest follow-up.
160
 Prior to transplant, 7 de novo patients and 3 
switch patients had an eGFR < 30 (severe impairment or end-stage renal failure), and 
ten patients required continuous veno-venous filtration (CVVH) immediately post-
transplant. At latest follow-up, of 42 de novo patients, 17 (40%) showed mild 
impairment (GFR 60-90), and 6 (14%) showed moderate renal impairment (GFR 30-60; 
mean follow-up 1.7 years). Of 58 patients originally taking ciclosporin (switch group), 
30 (52%) showed mild impairment, and 6 (10%) had moderate impairment (mean 
follow-up 5.3 years). No patients from either group had an eGFR < 30 at the end of the 
study period. 
Chapter 6  Tacrolimus in paediatric heart transplantation 
 106 
 
 
Figure 6.1 Change in renal function over time, expressed as eGFR. In the Switch group, renal 
function decreased immediately post-transplant, and recovered only after switching from ciclosporin to 
tacrolimus. Those patients receiving tacrolimus immediately post-transplant had no such fall in eGFR, but 
showed an improvement in renal function over the first 6 months post-transplant. 
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6.3.2 Blood pressure 
Anti-hypertensive treatment was required by 23/42 (55%) of patients in the de novo 
group one year post-transplant, and 25/42 (60%) at latest follow-up (p = 0.659; mean 
follow-up 1.8 years) (Figure 6.2). In the switch group, 39/58 (67%) required anti-
hypertensive treatment at the point of switch from ciclosporin to tacrolimus, which fell 
to 21/58 (36%) at latest follow-up (p = 0.001; mean 3.7 years following switch). 
 
 
 
Figure 6.2 Anti-hypertensive use (as a surrogate marker for hypertension) in switch and de novo 
groups. The upper panel illustrates a reduction anti-hypertensive use when patients were switched from 
ciclosporin to tacrolimus. 
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6.3.3 Glucose metabolism 
Data were available on 99 of the patients. There was no difference between the switch 
and de novo groups with regards to mean fasting blood glucose levels: de novo group 
5.2 mmol/l and switch group 5.1 mmol/l (p = 0.394). Since clinically relevant values 
have defined cut-offs (normoglycaemic, glucose intolerant, and diabetic) the data was 
also analysed categorically. Again, there was no difference between the switch and de 
novo groups (Pearson chi-square: χ2 (df = 2, n = 99) = 0.936, p = 0.626, Table 6.2). One 
patient from each group had clinical diabetes mellitus, one of whom had a body mass 
index (BMI) of 33. Both patients require only oral hypoglycaemic treatment. 
 
Fasting 
Glucose 
Mean (SD) < 6 mmol/l 
Normal 
6-7 mmol/l 
Glucose 
intolerance 
> 7 mmol/l 
Diabetes 
mellitus 
De novo 5.1 (±1.4) 31 (72%) 11 (26%) 1 (2%) 
Switch 5.2 (±0.8) 45 (80%) 10 (18%) 1 (2%) 
 
Table 6.2 Fasting glucose in the de novo and switch groups. Values other than mean are n (%). 
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Figure 6.3 Glucose intolerance in switch and de novo groups. 
 
6.3.4 Lipid metabolism 
Data were available on 97 of the patients. There was no difference in the cholesterol or 
triglyceride levels between the de novo and switch groups (median follow-up time for 
this analysis was 3.1 years) (Table 6.3). Median fasting blood triglyceride level was 
0.79 mmol/l in the de novo group, and 0.77 mmol/l in the switch group (p = 0.873). 
Mean cholesterol was 3.16 mmol/l in the de novo group, and 3.07 mmol/l in the switch 
group (p = 0.522). Again, as there are well-defined clinical thresholds with regards to 
cholesterol levels (borderline (> 4.4 mmol/l) and elevated (> 5.2 mmol/l)), data was re-
analysed categorically, using Pearson‘s chi-square. 3/44 of the de novo group had 
borderline cholesterol levels (4.4-5.2 mmol/l) and 1/53 of the switch group had an 
elevated cholesterol level (> 5.2 mmol/l); all other patients had normal cholesterol 
values (< 4.4 mmol/l). 
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 De novo Switch p 
Fasting triglycerides (mmol/l) (median, 
range) 
0.79  
(0.35-3.89) 
0.77  
(0.36-1.14) 
0.87 
Fasting cholesterol (mmol/l) (mean, SD) 3.16 ± 0.73 3.07 ± 0.68 0.52 
    
Cholesterol category    
Normal (< 4.4 mmol/l) 41 (93%) 52 (98%) 0.22 
Borderline (4.4-5.2 mmol/l)  3 (7%) 0 (0%) 
Elevated (> 5.2 mmol/l)  0 (0%) 1 (2%) 
 
Table 6.3 Fasting cholesterol and triglyceride levels.  
 
39/40 (98%) of the de novo group and 43/50 (86%) of the switch group were known to 
be taking statins at the point of testing (Pearson‘s chi-square p = 0.06). The mean 
cholesterol level was 3.1 mmol/l in those on statins, and 3.4 in those not taking statin 
therapy (p = 0.28). All four of the patients with a borderline or elevated cholesterol level 
were on pravastatin. The median triglyceride level was 0.75 mmol/l for those on statins 
and 1.06 for those not on statins (p = 0.02). There was no correlation between statin 
dose (either absolute value, or dose/kg body weight) and triglyceride or cholesterol 
level. 
6.3.5 Other parameters 
During the follow-up period, 10 patients from the switch group, and 3 from the de novo 
group died. Within each group, 5 patients were diagnosed and treated successfully for 
post-transplant lymphoproliferative disease. No other malignancies were diagnosed 
within the entire cohort. 
Chapter 6  Tacrolimus in paediatric heart transplantation 
 111 
6.4 DISCUSSION 
These data represent an encouraging review of the use of tacrolimus in a large cohort of 
paediatric heart transplant recipients. Whilst some patients did suffer from 
complications that may be linked to tacrolimus use, the overall incidence was not high. 
Moreover, those patients who had previously been taking ciclosporin exhibited an 
improvement in renal function and a decrease in the need for anti-hypertensive 
medication. 
 
The estimation of renal function in heart transplant recipients is of obvious importance, 
but producing meaningful and accurate values is difficult, especially in the paediatric 
age group. I have attempted to overcome these problems by using the Schwartz formula 
to estimate GFR, and, by using analysis based on paired estimates in each patient, I 
have minimized the potential bias of pre-transplant renal impairment, poor muscle bulk 
and hyperfiltration injury. Previous comparative assessment of the renal side-effects of 
tacrolimus and ciclosporin using direct measurement and eGFR did not find one 
medication to be superior to the other.
163
 This study suggests that, in contrast to 
ciclosporin, tacrolimus use post-transplant was compatible with a significant 
improvement in renal function associated with improved cardiac output in the first six 
months. I have also shown a similar improvement in renal function in those switched 
from ciclosporin to tacrolimus after at least six months post-transplant. In addition, de 
novo patients showed at least stability ineGFR after the first six months, which 
potentially corresponds to cessation of steroid therapy or lower levels of tacrolimus 
further out from transplant (mean tacrolimus level was 8.3 μg/l at 6 months, and 7.5 μg/l 
at one year). 
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It is important to remember, however, that average values across a cohort can mask a 
subsection with some degree of impairment. I therefore performed a secondary analysis 
of the proportion of patients with some degree of renal insufficiency, discovering that at 
latest follow-up, 47% of the entire group had mild impairment, and 12% moderate 
impairment (according to the National Kidney Foundation guidelines).
160
 The potential 
aetiology of this injury is multifactorial: pre-renal failure occurs during low cardiac 
output prior to and immediately after transplant, as well as during cardiopulmonary 
bypass, and can be exacerbated with necessarily aggressive diuretic treatment in the 
early post-transplant phase. Clearly, renal function must continue to be watched closely 
in all recipients. However, it is encouraging that despite poor renal function prior to 
transplant, and the need for peri-operative CVVH in ten patients, none of these 100 
patients currently have severe renal impairment, and that function improved in those 
switched from ciclosporin. 
 
Hypertension remains an important issue post-transplant. The prevalence in this group 
(as defined by those requiring treatment) compares favourably to previous adult 
studies
164
 and the International Society‘s paediatric report.95 Again, although tacrolimus 
has been implicated, the aetiology of hypertension is multifactorial, and the GOS 
institutional policy of withdrawing steroid treatment within 6-months post-transplant 
may have had influence. It might also be expected that as time passes, not only will 
target tacrolimus levels diminish, but also the hypertensive effect of oversized donor 
hearts might decrease, and these two points may explain why the switch group (who 
were further out from transplant) had less requirement for anti-hypertensive treatment. It 
is encouraging, however, to notice that when patients were switched from ciclosporin 
they displayed a contemporaneous fall in the requirement for blood pressure medication, 
which may reflect the less severe hypertensive side effect profile of tacrolimus shown 
by Taylor et al. in adults.
164
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There is also concern over the potential diabetogenic effects of tacrolimus.
165
 Again, it 
is not the sole potential aetiological agent, with steroid treatment also culpable.
166
 The 
overall level of post-transplant diabetes here is lower than other published series,
165
 
which may partly be the result of the withdrawal of steroids by six months. One of the 
two patients with diabetes in this sample had a BMI of 33 at the time of diagnosis, 
which would certainly have accelerated her diabetes; she is now adequately controlled 
with oral antihyperglycaemic therapy. None of the 100 patients in this cohort currently 
require insulin. However, it is again prudent to stress that a significant proportion of 
these patients – in this case just over one-fifth – showed glucose intolerance (even in 
this relatively short follow-up period), and it is probable that some of them will go on to 
require antidiabetic therapy in the future. 
 
The results concerning lipid metabolism show a similar pattern, with the vast majority 
of patients within the normal range. Previous studies have also concluded that 
hyperlipidaemia may be less common in patients on tacrolimus than on ciclosporin.
167, 
168
 The transplant team at Great Ormond Street now routinely prescribes pravastatin 
(which may not only lower cholesterol levels, but also reduce coronary allograft 
vasculopathy),
169
 and these results should of course be viewed in this light. All four 
patients with abnormal cholesterol levels were being treated with sub-maximal levels of 
pravastatin, and we anticipate that the subsequent increase in dose will result in a 
lowering of their values. 
 
The influence of statin therapy on the side-effect profile of tacrolimus may not be 
limited to its lipid lowering effects, but also via modulatory influences on the renal 
system. Statins have been shown to slow decline of GFR and decrease proteinuria
170
 in 
chronic kidney disease, and have also been linked to decreased renal failure in heart 
transplant patients.
171
 Similarly, early reduction in steroid exposure may also be helping 
to moderate the side effects of tacrolimus by reducing renal injury. Prolongation of renal 
function in this manner may be linked to the decrease in hypertension and diabetes in 
this cohort. 
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6.5 CONCLUSION 
In summary, this chapter records post-transplant complications in a sizeable cohort of 
paediatric heart transplant recipients. Despite its retrospective nature, the large 
population studied have provided valuable insight into the four areas discussed (renal 
function, hypertension, and lipid and glucose metabolism), which have all previously 
been linked to tacrolimus use.
158
 In this group, the prevalence of these disorders was 
relatively low compared to other studies, and those switched from ciclosporin showed a 
contemporaneous decrease in side-effect profile (although it is impossible to be certain 
that the switch was the major factor). These results suggest that, in the current era of 
steroid-free immunosuppression and widespread use of statins, the side-effect profile of 
tacrolimus appears to have been partly ameliorated. 
 CHAPTER 7 
PERIPHERAL ENDOTHELIAL DYSFUNCTION AND 
CYTOMEGALOVIRUS REPLICATION IN 
PAEDIATRIC HEART TRANSPLANTATION 
 
This chapter investigates a potential role of cytomegalovirus (CMV) on cardiac 
allograft vasculopathy (CAV) – the major limiting factor to the long-term success of 
paediatric heart transplantation. CMV has been shown to be a significant risk factor for 
the development of CAV. Previous work has demonstrated CMV DNA in leukocytes in 
the absence of direct allograft infection, suggesting that vascular changes may not be 
limited to the allograft. Systemic arterial endothelial function was assessed using high-
resolution ultrasound to determine brachial artery flow mediated dilatation (FMD) in 
50 paediatric heart transplant recipients (aged 8 to 17 years, 27 male). Patients were 
separated into two groups according to CMV status: those without evidence of CMV 
replication post-transplant (n = 38, 19 male); and patients with evidence of viraemia 
post-transplant (n = 12, 8 male). No patient had detectable viraemia at the time of 
study. FMD was significantly impaired in patients with CMV replication post-transplant 
(6.64 ± 1.12%; mean ± S.E.) compared to those without (9.48 ± 0.56%; p = 0.02). This 
difference remained after adjustment for age, time since transplant and medication. 
Pre-transplant recipient and donor CMV status and traditional CMV risk were not 
associated with FMD. This chapter shows therefore that CMV replication following 
cardiac transplantation is associated with chronic endothelial dysfunction in the 
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systemic circulation in children. The implication for both systemic and coronary 
vascular health is examined in the following chapter. 
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7.1 INTRODUCTION 
Although short- and medium-term results are improving, long-term survival for 
paediatric transplant recipients is limited by cardiac allograft vasculopathy, an 
accelerated form of obliterative coronary disease. Human cytomegalovirus (CMV) is 
associated with increased risk of post-transplant coronary vasculopathy.
172, 173
 A 
previous study from Great Ormond Street has shown CMV serology to be an important 
factor in allograft vasculopathy of paediatric recipients.
174
 Coronary endothelial 
dysfunction is associated with CMV infection
175 
and the later development of transplant 
vasculopathy.
176
 Recent work has shown that low-level systemic CMV infection is 
common after transplantation,
177
 although infection of the heart itself is rare.
178
 It is 
therefore possible that the coronary vascular disease attributed to CMV may be driven 
by the consequences of low grade systemic infection – rather than infection of the 
transplant organ – which may have broader vascular consequences. However, the effect 
of post-transplant CMV on the systemic vasculature is unknown. This chapter tests the 
hypothesis that CMV replication could affect systemic endothelial function after 
paediatric cardiac transplantation.  
 
Chapter 7 Peripheral endothelial dysfunction & CMV replication post-transplantation 
 118 
7.2 METHODS 
7.2.1 Study population and design 
All children over the age of eight years who had previously had a heart transplant 
returning to Great Ormond Street Hospital for their annual review between October 
2004 and August 2006 were invited to take part in the study. Exclusion criteria were: 
coexisting vascular disease, patient or parent refusal, active intercurrent systemic 
illness, and clinical or echocardiographic evidence of heart failure (left ventricular 
fractional shortening < 30%). Fifty-two patients were invited, two of whom were 
excluded due to lack of parental consent. The remaining fifty patients (aged 8-17 years, 
27 male) were enrolled, and were separated into two groups based on CMV status: 
group 1 (n = 38, 19 male) – those without evidence of CMV replication post-transplant 
(negative polymerase chain reaction [PCR] and no change in CMV IgG post-
transplant); and group 2 (n = 12, 8 male) – patients with evidence of post-transplant 
viraemia (positive CMV PCR and/or seroconversion from negative to positive CMV 
IgG). No patient from either group was viraemic at the time of assessment. All patients 
were free from angiographic evidence of CAV, and were assessed for conventional 
vascular risk factors (hypertension, smoking, diabetes, lipid profile) and transplant and 
medication history. 
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Characteristics No CMV replication CMV replication p 
Number of patients 38 12 - 
Age (years) 14.5 ± 0.4 13.1 ± 0.6 0.07 
Male sex 19 (50) 8 (67) 0.32 
Heart rate (median, b.p.m. (IQ 
range)) 
91 (79 – 104) 89 (84 – 97) 0.75 
Systolic blood pressure (mmHg) 113 ± 2 110 ± 3 0.53 
Diastolic blood pressure (mmHg) 71 ± 1 65 ± 3 0.06 
Cholesterol (mmol/l) 3.12 ± 0.11 3.09 ± 0.21 0.88 
Triglycerides (mmol/l) 0.88 ± 0.06 1.01 ± 0.14 0.29 
HDL (mmol/l) 1.02 ± 0.05 1.03 ± 0.07 0.96 
LDL (mmol/l) 1.73 ± 0.11 1.59 ± 0.19 0.55 
Glucose (median, mmol/l (IQ 
range)) 
5.10 (4.80 – 5.78) 5.20 (4.40 – 6.00) 0.59 
hs CRP (median, mg/l (IQ range)) 0.86 (0.25 – 3.55) 0.45 (0.11 – 0.70) 0.10 
Creatinine (μmol/l) 67.7 ± 2.8 70.6 ± 8.0 0.66 
 
Table 7.1 Baseline characteristics of study participants. HDL – high-density lipoprotein, LDL – low 
density lipoprotein; hs CRP – high-sensitivity C-reactive protein, IQ range – interquartile range. All blood 
tests are fasting values. Values are expressed as mean ± S.E.M. or frequency (percentage), unless 
otherwise specified.  
7.2.2 Conventional and transplant-related risk factors 
There were no smokers or diabetics amongst the cohort. There was no significant 
difference between the groups with respect to age, sex, heart rate, blood pressure, or 
blood glucose or lipid levels (Table 7.1). Renal function – measured by serum creatinine 
and estimated glomerular filtration rate (data not shown) – was similar in both groups. 
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Transplant-related variables and drug use were comparable between the groups (Table 
7.2). A double-therapy immunosuppressant regime of calcineurin inhibitor and a purine 
synthesis inhibitor was used except when the latter was not tolerated, when single agent 
therapy was used. No patients were receiving steroids at the time of the scan. 11 patients 
were donor-positive, recipient-negative for CMV IgG at transplant (seven in group 1, 
four in group 2). Of these, 6 received CMV prophylaxis (valganciclovir 450mg o.d.) for 
3 months post-transplant (three in group 1, three in group 2). 
 
Characteristics No CMV replication CMV replication p 
Age at transplant 
(median, years (IQ 
range)) 
11 (6 – 15) 9 (7 – 13) 0.55 
Donor age (years) 19.3 ± 2.0 21.7 ± 4.3 0.57 
Ischemic time 
(mins) 
196 ± 11 156 ± 18 0.08 
Episodes of acute 
rejection (median 
(IQ range)) 
0 (0 – 1) 0 (0 – 1) 0.64 
Years since 
transplant (median, 
(IQ range)) 
3.63 (1.40 – 7.97) 2.68 (1.58 – 5.07) 0.67 
Statin use 34 (90) 9 (75) 0.33 
Double 
immunosuppression 
34 (90) 10 (83) 0.62 
 
Table 7.2 Transplant related variables. Values are expressed as mean ± S.E.M., or frequency 
(percentage), unless otherwise specified. 
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7.2.3 Peripheral endothelial function measurements 
Endothelial dysfunction was studied as previously described.
179
 Briefly, the subjects 
rested supine for 10 minutes, having abstained from caffeine and fatty food for four 
hours prior to the scan. The right brachial artery was then imaged using high-resolution 
ultrasound (Prosound SSD-5500, ALOKA, Japan). Forearm ischemia was induced by 
inflating a blood pressure cuff to 200mmHg for five minutes; reactive hyperaemia 
followed cuff deflation. Changes in brachial artery diameter were measured offline 
using an automated edge detection system (Brachial Tools, Medical Imaging 
Applications, Iowa) and calculated as a percentage change from baseline diameter. 
Blood flow was measured continuously using a pulsed-wave Doppler signal. Maximal 
increase in blood flow within 15 seconds of cuff release was expressed as a percentage 
change from baseline flow (± standard error). Endothelium independent vasodilator 
response to 25µg sublingual glyceryl trinitrate (GTN) was then measured and expressed 
as a percentage change in diameter from baseline. Blood pressure was initially taken 
after resting for five minutes and also after flow meditated dilatation (FMD) and GTN 
studies using an Omron M5-I sphygmomanometer. All studies were performed in a 
temperature-controlled vascular laboratory by a single trained operator, who was 
blinded to all clinical history of the patients, including CMV variables. 
7.2.4 CMV Measurements  
Blood for CMV analysis was taken prior to transplant, at monthly clinic visits post-
transplant in the first year, and annually thereafter. DNA was extracted from 200µl of 
EDTA whole blood using QI Amp Blood Mini Kits (Cat no. 80204, www.qiagen.com) 
according to the manufacturer‘s instructions. CMV DNA was quantified in whole blood 
by a method developed by Garson J. and Tedder R. at University College Hospital, 
London (personal communication) that was standardized against samples distributed by 
the European Quality Control for Molecular Diagnosis programme (info@qcmd.org). 
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The mastermix for the reaction consisted of 10µl of Taqman universal mastermix (ABI 
Biosystems Cat No 4304437) for tests run on the ABI 7000 and 7300 machines, or 10µl 
of Taqman fast Master Mix (ABI Cat No 4352042) for tests run on the ABI 7500 
machine. 1µl (10pm/µl) CMV forward primer GCA TGC GCG AGT GTC AAG AC; 
1µl (10pm/µl) reverse primer GTT ACT TTG AG(CT) GCC ATC TGT TCC T; 2µl 
(10pm/µl) probe FAM- TGC GCC GTA TGC TGC TCG ACA- TAMRA; 1µl of 
nuclease free water and 10µl of DNA template. Cycling conditions were as follows: 
ABI 7000, ABI 7300: 1 cycle 50˚C for 2 minutes, 1 Cycle 95˚C for 10 minutes, 45 
cycles at 95˚C for 15 seconds and a final step at 60˚C for a minute; ABI 7500 fast 
machine: 1 cycle 5˚C for 20 secs followed by 45 cycles at 95˚C for 3 seconds and a 
final step of 60˚C for 30 secs. Viral loads were obtained by reference to ten CMV 
(strain AD169 culture in human embryo lung fibroblasts) standards that were included 
in each run, ranging from 100 to 2 million copies/ml extract. Assays were considered 
valid if the correlation coefficient for the standards was > 0.99 and the gradient between 
-3.3 and -3.6. CMV IgG was measured by a Vidas machine (Biomerieux). 
7.2.5 Statistical analysis 
Data were analysed with SPSS 13.0 for Windows (SPSS Inc.). Two-group comparisons 
of means were performed with the unpaired Student t-test for normally distributed data 
(age, cholesterol, triglycerides, creatinine, blood pressure, donor age, ischemic time, 
flow mediated dilatation and dilatation to GTN) and the Mann-Whitney U test for non-
normally distributed data (age at transplant, time since transplant, episodes of acute 
rejection, heart rate, serum glucose, and hsCRP), following testing for normality using 
the Kolmogorov-Smirnov test. Multiple-group comparisons were conducted using a 
one-way ANOVA (CMV risk stratification). Comparisons of proportions were 
calculated using Fisher‘s exact test (sex, medications). Linear regression with multiple 
predictors was performed to explore the relationship between CMV status and FMD 
adjusting for age, time since transplant, and medication. 
 
The study was approved by the Great Ormond Street Hospital Ethics Committee. 
Informed consent was obtained from all patients‘ parents, and consent/assent was taken 
(as appropriate) from the patients themselves. 
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7.3 RESULTS 
7.3.1 Vascular function 
No patients were CMV PCR positive at the time of the brachial scan. The mean time 
from last positive PCR to scan was 23 months, and only two patients had a positive 
PCR within the 6 months prior to the scan. Brachial artery flow mediated dilatation 
(FMD) was significantly reduced in patients with previous active CMV viraemia post-
transplant compared to patients without evidence of replication (6.64 ± 1.12% vs. 9.48 ± 
0.56%, p = 0.02; Figure 7.1). This difference remained significant when adjusted for 
age, time since transplant, and medication (p = 0.02). In contrast, response to GTN was 
comparable between the two groups (10.68% and 10.55%, respectively), indicating that 
the difference in FMD was not due to differences in smooth muscle function. Baseline 
arterial diameter (2.96mm ± 0.079 vs. 3.23 ± 0.12, p = 0.094) and flow (reactive 
hyperaemia 489 ± 41% vs. 437 ± 128%, p = 0.618) were also similar in groups 1 and 2.  
 
The patients were also analysed according to their donor CMV status, recipient pre-
transplant status and traditional CMV risk stratification
180
 (Table 7.3). None of these 
three variables was predictive of FMD. There was no correlation between maximum 
CMV PCR detected or duration of PCR positivity and FMD. 
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Figure 7.1 Flow mediated dilatation and GTN response. 
 
Criterion Value n FMD p 
Donor CMV 
status 
Positive 19 9.03 ± 0.89 0.91 
Negative 29 8.90 ± 0.67 
Recipient CMV 
status 
Positive 15 8.82 ± 0.72 0.84 
Negative 33 9.06 ± 0.70 
Traditional risk 
stratification 
High-risk 11 9.46 ± 1.40 0.92 
Intermediate-risk 16 9.00 ± 0.69 
Low-risk 20 8.95 ± 0.85 
 
Table 7.3 Mean % FMD ± S.E.M., grouped by pre-transplant CMV variables. High-risk: donor CMV-
positive/recipient CMV-negative; intermediate-risk: recipient CMV-positive; low-risk: donor and 
recipient CMV-negative. N.B. The donor CMV status was not available in two cases. The recipient pre-
transplant status was not available in two cases. 
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7.4 DISCUSSION 
This chapter presents the first study to link CMV and systemic vascular dysfunction 
following heart transplantation. It demonstrates that children with evidence of CMV 
replication following heart transplant (as shown by positive PCR or seroconversion) 
have significantly worse systemic endothelial function. Although impaired endothelial 
dysfunction has been described in children with symptoms of acute viral illnesses,
181
 
these patients had neither signs of infection nor evidence of CMV DNA in their blood at 
the time of vascular study, suggesting a more chronic association between CMV and 
vascular function. The relationship between active CMV replication and reduced FMD 
remained after adjustment for multiple potential confounding variables. The young age 
of the cohort minimises the impact of many of the potential confounders for systemic 
vascular disease such as smoking, hypertension and diabetes. In addition, there was no 
relationship to known risk factors such as inflammation (hsCRP), lipids, or blood 
pressure. This abnormality in endothelial function may have important implications for 
the later systemic vascular health of young transplant recipients, and may reflect 
changes in the coronary circulation of relevance to the pathogenesis of CAV. 
 
While systemic vascular health is clearly important for children after transplantation, it 
is coronary vasculopathy that limits their long-term outcome.
89, 182
 The pathogenesis of 
this disease is complex and multifactorial, and currently incompletely understood. 
However, studies have highlighted the relationship between CMV and allograft 
vasculopathy in adults
172, 173, 175
 and, more recently, in children.
174
 One of the hallmarks 
of allograft vasculopathy is endothelial dysfunction.
176
 Although the mechanisms by 
which CMV may cause vasculopathy are unknown, it is likely that dysfunction of the 
endothelium is important. CMV has been shown to infect endothelial cells,
183
 and is 
related to coronary vasomotor dysfunction in heart transplant patients.
175
 This work now 
extends these findings to the systemic vasculature. 
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In previous adult studies, CMV-negative recipients of CMV-positive hearts have shown 
an increased cardiovascular risk.
184, 185
 In this study, no relationship was seen between 
systemic endothelial function and donor or recipient CMV status, the traditional 
markers of risk of CMV disease. CMV prophylaxis has reduced the risk of coronary 
disease in this group.
186
 However, in the majority of patients, no prophylaxis is given, 
and CMV infection involving leukocytes remains common.
177
 Evidence is accumulating 
that graft vasculopathy may be driven by the consequences of low-grade systemic 
infection and reduced by its suppression.
186
 Pre-transplant CMV seropositivity (and 
consequent lack of aggressive prophylaxis) appears associated with coronary lumen 
loss.
187
 This is consistent with our previous work on CMV and graft vasculopathy in 
children,
174
 and with our current findings, where viral DNA was documented in patients 
CMV IgG positive prior to transplantation. That subclinical CMV infection may have a 
systemic endothelial effect is further illustrated by our finding that eleven of the twelve 
children with post-transplant CMV replication did not go on to develop overt CMV 
disease, yet nevertheless showed reduced systemic endothelial function. 
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A recent study by Tu et al has investigated the immune response to subclinical CMV 
infection in recipients who were CMV IgG positive at transplant.
188
 This showed that 
patients with CMV-specific CD4 T-cells in the first month post-transplant showed less 
coronary artery lumen loss than those without. These ―early responders‖ were also 
found to have low/undetectable levels of CMV by PCR (mean < 40 copies/1x10
5
 
polymorphonuclear cells (PMN), compared to > 250 copies/1x10
5
 PMN in those 
without the early response). Although the present study was not designed to explore T-
cell responses, and the study populations are different in terms of CMV status at 
transplant, it is probable that there is overlap of our group without detectable virus and 
the early responder group of Tu et al. I would hypothesize that similar immune 
mechanisms may be working in my study, protecting against systemic vascular injury. 
A follow-up project investigating immune responses and systemic arterial function is 
required to explore this theory in detail. However, both my results and the work by Tu 
et al demonstrate that subclinical CMV infection is associated with later vascular 
abnormalities and that those without evidence of viral replication have a more 
favourable vascular outcome. 
 
The precise mechanism by which prior CMV replication causes on-going endothelial 
dysfunction is unclear. It is possible that low level CMV viraemia (undetectable by 
current assays) or persistent infection of leukocytes or endothelial cells affects the 
vasculature directly. Alternatively, either of these mechanisms may impair endothelial 
function indirectly through chronic immune activation. It is also possible that these 
observations are a lasting consequence of a prior endothelial insult, sustained at a time 
of higher viral load.  
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Quantification of endothelial function using ultrasound assessment of brachial artery 
FMD is a well-validated, non-invasive method. Recently, the first large, prospective 
study has shown FMD to be predictive of future cardiovascular events in adults.
189
 The 
prognostic value in younger patients remains unproven, as the cardiovascular endpoints 
typically present decades later. FMD is also predictive of coronary endothelial function 
in adults,
190
 raising the possibility that depressed FMD in these children reflects 
impaired coronary endothelial function relevant to the progression of CAV. Certainly, a 
non-invasive marker of transplant coronary vasculopathy would be diagnostically 
attractive, particularly in the paediatric age group. Furthermore, as FMD is a dynamic 
measurement, it may be useful as a therapeutic marker in clinical trials assessing the 
response to CMV infections in the transplant population. 
 
All children in this study had angiographically normal coronary arteries, although a 
more sensitive assessment of the coronary vasculature – such as intravascular 
ultrasound – would have been useful. Although this technique is limited by the size of 
coronary arteries in young children, it is possible in older children and adolescents. The 
monitoring of CMV viral load was limited to outpatient attendances and it is possible 
that some patients could have experienced low level CMV replication which was not 
detected; this was in part accounted for by checking for seroconversion in those patients 
who were CMV negative at transplantation. 
7.5 CONCLUSION 
This chapter reveals for the first time that CMV replication following cardiac 
transplantation is associated with chronic endothelial dysfunction in the systemic 
circulation in children. The implication for both systemic and coronary vascular health 
remains unknown, however. This is explored in the next chapter.  
 CHAPTER 8 
CYTOMEGALOVIRUS CAUSES FUNCTIONAL AND 
MORPHOLOGICAL CHANGES IN SYSTEMIC AND 
CORONARY VASCULATURE OF PAEDIATRIC 
HEART TRANSPLANT RECIPIENTS BUT NOT IN 
HEALTHY CHILDREN 
Cytomegalovirus (CMV) is thought to be an important risk factor for post-transplant 
vascular disease, particularly in young recipients. This chapter reports the effects of 
CMV on the coronary and systemic arteries of paediatric heart transplant recipients. In 
addition, the systemic arteries of normal children were investigated, to elucidate 
whether CMV changes occur purely in the immunocompromised post-transplant setting. 
37 paediatric heart transplant recipients (9.3-17.3 years, mean 14.2) and 69 healthy 
controls (6.3-17.5 years, mean 12.2) were investigated. Coronary intimal-medial area 
of transplant recipients was measured with intravascular ultrasound. Systemic vascular 
health was assessed in both groups with brachial flow mediated dilatation (FMD) and 
carotid intimal thickness (cIMT). Comparisons were made using the Student’s t-test. 19 
(51%) transplant recipients and 21 (30%) controls were CMV IgG-positive at 
investigation. Mean time from transplant was 4.7 years (range 1 – 12.4 years). 
Coronary intimal-medial area was increased in CMV-positive compared to CMV-
negative transplant recipients (23.9% vs. 17.2%; p = 0.01). cIMT was also increased 
(0.50mm v 0.47mm, p < 0.05), and FMD reduced (6.9 vs. 9.3%; p < 0.05). In contrast, 
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there was no difference between CMV-positive and negative healthy controls with 
regards to cIMT (0.44 vs. 0.45; p = 0.26) or FMD (9.5 vs. 9.4%; p = 0.87). This 
chapter represents evidence linking CMV and coronary allograft vasculopathy in 
paediatric transplant recipients. Moreover, CMV-positive patients exhibit 
morphological and functional impairment of their native arteries. CMV does not inflict 
such damage in immunocompetent hosts. These findings strengthen the proposal for 
therapy against CMV post-transplantation.  
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8.2  INTRODUCTION 
With surgical and intensive care modifications improving short-term survival, cardiac 
allograft vasculopathy (CAV) has become the major limiting factor to the success of 
adult and particularly paediatric heart transplantation.
87, 88
 While 15-year survival after 
transplant might be considered an acceptable outcome after adult transplantation, it 
represents the prospect of death or re-transplantation as a young adult for paediatric 
recipients.  
 
Cytomegalovirus (CMV) is a herpes virus which has a predilection for harmful 
interaction with endothelial cells,
191
 and has been associated with morphological 
changes in the coronary vasculature after heart transplantation.
172, 173, 175
 However, the 
importance of CMV in adult allograft vasculopathy is not certain.
192
 Conventional risk 
factors such as smoking, hypercholesterolaemia, obesity, hypertension and diabetes 
have been implicated in transplant coronary disease and pre-existing (donor) coronary 
disease from older donors has also been identified as a risk factor. Paediatric transplant 
recipients, generally devoid of these confounders, are a more homogeneous population 
to study the effects of CMV on vasculopathy.  
 
Work from Great Ormond Street Hospital has previously shown that CMV is an 
important risk factor for later mortality after paediatric heart transplantation and is 
associated with an increased incidence of angiographic coronary disease.
174
 However, 
angiography is a crude assessment of transplant coronary disease, and intravascular 
ultrasound is generally accepted to be a more sensitive technique,
193-195
 although it has 
been used in few paediatric studies.
196, 197
 The previous chapter has also shown that 
CMV infection has a systemic endothelial effect in paediatric transplant recipients,
198
 
but concomitant systemic structural arterial damage has not been assessed in this 
population.  
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Therefore, in this chapter, I have extended those initial studies into the role of CMV and 
paediatric allograft vasculopathy by using intravascular ultrasound. In the same 
children, I have investigated disease beyond the graft/recipient interaction by assessing 
the carotid intima/media thickness and brachial flow-mediated dilatation. Furthermore, 
as the impact of CMV seropositivity on the systemic vasculature of immunocompetent 
children is unknown, I have investigated the carotid and brachial arteries of healthy non-
transplanted children, thus exploring whether CMV-modulated changes are limited to 
the immunosuppressed state. 
8.2 METHODS 
8.2.1 Study Population and Design  
All heart transplant recipients over the age of nine years at Great Ormond Street 
Hospital were invited to take part in the study at the time of their annual coronary 
angiography. Only patients who were at least one year post-transplant were included, in 
order to minimize the effects of donor disease, and allow post-transplant changes to 
occur. Exclusion criteria were: patient or parent refusal; active intercurrent systemic 
illness; active CMV replication as measured by PCR for CMV DNA; and clinical or 
echocardiographic evidence of heart failure (left ventricular fractional shortening < 
30%). A double therapy immunosuppressant regimen of calcineurin inhibitor or 
sirolimus and a purine synthesis inhibitor was used except when the latter was not 
tolerated, when single agent therapy was used. No patients were receiving steroids at the 
time of the scan. In total, 37 transplant recipients (22 male, aged 9.3-17.3 years, mean 
14.2) and 69 aged-matched healthy controls (32 male, age 6.3-17.5 years, mean 12.2) 
were included, and divided into two groups based on CMV IgG status at the time of 
their investigations (19 transplant recipients (51%) and 21 controls (30%) were CMV-
positive).  
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8.2.2 Coronary intimal thickness measurements 
Intravascular ultrasound (IVUS) was performed during routine post-transplant coronary 
angiography. After maximal dilatation with intracoronary glyceryl trinitrate (GTN) 
(150μg), a 3.5F 30-Mhz IVUS catheter (Boston Scientific, Natick, MA) was advanced 
over a 0.014‖ coronary guidewire into the distal left anterior descending (LAD) 
coronary artery through a 6F guide catheter. A suitable mid/distal LAD coronary artery 
segment was identified and an automated pullback at 0.5 mm/second was performed. 
Images were acquired using a Galaxy 2 IVUS machine (Boston Scientific). Further 
analysis of digitally stored procedures was performed offline in accordance with the 
American Consensus statement for intravascular ultrasound,
199
 and as described 
previously.
200
 Off-line, a segment of the coronary artery was identified between two 
identifiable branch points. Suitable cross-sectional images were selected approximately 
1 mm apart (60 frames) by a single operator blinded to the clinical and CMV status of 
each patient. A minimum of fifteen digitised images were then analysed with semi-
automatic edge detection software (QIVUS, Medis Medical Imaging Systems, 
Netherlands) for the area of the external elastic membrane (EEM) and the internal 
lumen area (ILA). Intimal-medial area was selected as the most appropriate parameter 
to assess the diffuse coronary disease seen in the transplant population, and was 
calculated as a percentage of the EEM area occluded by intimal-medial thickening, thus: 
(EEM-ILA)/EEM x 100%. A mean value for intimal-medial area was calculated for the 
coronary segment imaged. 
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8.2.3 Carotid measurements 
Participants rested supine for 10 minutes before undergoing high resolution ultrasound 
scanning (7.5MHz transducer; Prosound SSD-5500, ALOKA, Japan) of right and left 
common carotid arteries. Arteries were imaged longitudinally, 1 cm inferior to the 
bifurcation. For IMT, a recording was taken of zoomed images triggered to the R wave 
of the ECG. Distension of the common carotid artery was measured using an echo-
tracking subsystem installed in the colour Doppler system.
201
 Ipsilateral brachial blood 
pressure was taken immediately after carotid measures using an M5-I 
sphygmomanometer (OMRON Corp., Japan), and analysis was performed offline. IMT 
was defined as the distance between the leading edge of the intima and the media-
adventitia interface, and was measured using ultrasonic calipers. Three measurements 
were taken in both the right and the left common carotid arteries, and a mean IMT 
calculated. For distension analysis, a minimum of 3 waveforms were selected using 
proprietary analysis software (ALOKA), and the distension calculated as an average of 
the difference between three peaks and troughs.
201
 
8.2.4 Brachial artery endothelial function 
Endothelial dysfunction was studied as previously described,
179
 and is recorded fully in 
section 7.2.3.  
8.2.5 Statistical analysis 
Data were analysed with SPSS 15.0 for Windows (SPSS Inc., Chicago, IL). Two-group 
comparisons of means were performed with the unpaired Student t-test for normally 
distributed data (percentage intimal-medial area, carotid intimal thickness, age, 
cholesterol, triglycerides, creatinine, eGFR, heart rate, blood pressure, donor age, 
ischemic time, time since transplant) and the Mann-Whitney U test for non-normally 
distributed data (episodes of acute rejection, serum glucose and hsCRP), following 
testing for normality using the Kolmogorov-Smirnov test. Comparisons of proportions 
were calculated using Fisher‘s exact test (sex, medications). Linear regression with 
multiple predictors was performed to explore the relationship between CMV status and 
vascular changes adjusting for age, time since transplant, and medication. 
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The study was approved by the Great Ormond Street Hospital Ethics Committee. 
Informed consent was obtained from all patients‘ parents, and consent/assent (as 
appropriate) was also taken from the patients themselves. 
RESULTS  
8.2.6 Conventional and transplant-related risk factors 
There were no smokers or diabetics amongst the transplant cohort. There was no 
significant difference between the CMV-positive and negative groups with respect to 
age, sex, heart rate, blood pressure, renal function (serum creatinine and estimated 
glomerular filtration rate (eGFR) by the Schwartz formula
159
) or blood glucose or lipid 
levels (Table 8.1). 
 
Parameter CMV IgG Negative CMV IgG Positive p 
Number of patients 18 19 - 
Age (years) 14.4 ± 0.5 13.9 ± 0.6 0.57 
Male sex 10 (56) 12 (63) 0.74 
Heart rate (b.p.m) 90 ± 3 89 ± 3 0.85 
Systolic blood pressure (mmHg) 112 ± 3 114 ± 3 0.58 
Diastolic blood pressure 
(mmHg) 
69 ± 3 66 ± 2 0.36 
Glucose (median, mmol/l (IQR) 5.1 (4.9 – 6.1) 5.0 (4.7 – 5.5) 0.16 
Cholesterol (mmol/l) 3.14 ± 0.14 2.91 ± 0.14 0.26 
Triglycerides (mmol/l) 0.78 ± 0.07 0.79 ± 0.07 0.94 
hs CRP (median, mg/l (IQR) 0.45 (0.22 – 2.22) 0.24 (0.1 – 0.71)  0.28 
Creatinine (μmol/l) 64 ± 4 67 ± 4 0.60 
Estimated GFR (ml/min/1.73m
2
) 92 ± 7 87 ± 5 0.59 
 
Table 8.1 Baseline characteristics of transplanted patients. All blood tests are fasting values. Values 
are expressed as mean ± S.E.M. or frequency (percentage), unless otherwise specified. Key: hs CRP – 
high-sensitivity C-reactive protein, IQR – interquartile range. 
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Transplant-related variables and medications were comparable between the groups 
(Table 8.2). 5 (26%) of the patients who were CMV IgG positive at the time of 
investigation had been CMV IgG negative at the time of transplant. Mean time from 
transplant to investigation was 4.7 years (range 1 – 12.4 years). 
 
Parameter CMV IgG 
Negative 
CMV IgG 
Positive 
p 
Age at transplant (years) 9.8 ± 1.1 9.2 ± 4.8 0.73 
Donor age (years) 20.5 ± 3.1 20.7 ± 3.8 0.97 
Ischemic time (mins) 206 ± 17 173 ± 15 0.17 
Episodes of acute rejection 
(median (IQ range)) 
0 (0 – 1) 0 (0 – 1) 0.52 
Time since transplant (years) 4.7 ± 0.8 4.7 ± 0.7 0.99 
Statin use 17 (94) 18 (95) 0.74 
Primary immunosuppression 
(tacrolimus:sirolimus:ciclosporin) 
17:1:0 17:1:1 1.0 
Additional immunosuppression 
(MMF:azathioprine:none) 
6:10:2 9:7:3 0.60 
Double immunosuppression 16 (89) 16 (84) 0.68 
 
Table 8.2 Transplant related variables. Values are expressed as mean ± S.E.M., or frequency 
(percentage), unless otherwise specified. 
Chapter 8 CMV and systemic and coronary arterial changes post-heart transplantation 
 137 
8.2.7 Vascular measurements – transplant recipients 
Coronary artery intimal thickness (as measured by percentage intimal-medial area) was 
significantly greater in CMV IgG positive patients compared to those who have 
remained CMV IgG negative (23.9% vs. 17.2%, p = 0.01) (Table 8.3). There was a 
similar discrepancy in mean carotid artery thickness (0.50 mm vs. 0.47 mm, p < 0.05). 
In addition, flow mediated dilatation of the brachial artery was impaired in those 
patients who were CMV IgG positive (6.9% vs. 9.3%, p < 0.05). In contrast, dilatation 
to GTN (a measure of endothelium-independent arterial function) was similar between 
the groups (10.6% vs. 9.8%, p = 0.68), confirming that the difference in FMD was 
endothelium-mediated. All differences remained significant when adjusted for age, time 
since transplant, and medication with a multivariable logistic regression model. 
 
Parameter CMV IgG Negative 
(n = 18) 
CMV IgG Positive 
(n = 19) 
p 
Coronary intimal index (%) 17.2 ± 1.3 23.9 ± 2.1 0.01 
Carotid intimal thickness 
(mm) 
0.47 ± 0.01 0.50 ± 0.01 < 0.05 
Brachial flow mediated 
dilatation (%) 
9.28 ± 0.94 6.89 ± 0.72 < 0.05 
Brachial GTN dilatation (%) 9.84 ± 1.13 10.55 ± 1.31 0.68 
 
Table 8.3 Vascular parameter results for heart transplant patients. 
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8.2.8 Vascular measurements – healthy children 
There was no significant difference in cIMT between CMV IgG positive and negative 
healthy children (0.44mm vs. 0.45mm, p = 0.26) (Table 8.4). FMD was also similar 
between these two groups (9.5% vs. 9.4%, p = 0.87). 
 
Parameter CMV IgG Negative  
(n = 48) 
CMV IgG Positive  
(n = 21) 
p 
Carotid intimal 
thickness (mm) 
0.44 ± 0.01 0.45 ± 0.01 0.26 
Brachial flow mediated 
dilatation (%) 
9.4 ± 0.46 9.5 ± 0.82 0.87 
 
Table 8.4 Vascular parameter results for healthy control children 
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8.3 DISCUSSION 
This chapter demonstrates the deleterious effects of CMV IgG positivity on the 
coronary arteries of paediatric transplant recipients by the sensitive method of IVUS. It 
also shows systemic functional and morphological damage in the brachial and carotid 
arteries of these same transplant recipients. These systemic effects indicate that CMV is 
not reliant on donor-host interactions for its vascular pathogenicity. However, these 
changes were not seen in control subjects, implying that the vascular disease is a post-
transplant event, related to CMV replication in the immunocompromised state. 
 
Cardiac allograft vasculopathy remains the most common cause of death after 5 years 
post-transplant in adults,
87
 and 3 years in children.
88
 Previous studies have concluded 
that CAV is less prevalent in paediatric than adult patients;
202
 indeed, the registry report 
of the International Society of Heart and Lung Transplantation reported that almost 
three-quarters of patients remained free from CAV at 8 years post-transplant.
203
 In 
reality, this is likely to be a significant underestimate based primarily on limited 
angiographic surveillance, and IVUS is now accepted as a much more sensitive tool for 
the diagnosis of vascular changes.
193, 204
 In contrast, a minority of adult patients will be 
completely free of vasculopathy on IVUS at 10 years post-transplant.
87
 Despite this, 20 
year-survival is a realistic hope for some patients following transplantation, which could 
be considered a good outcome for an adult where the mean age at transplant is over 50 
years.
87
 For a paediatric recipient, however, this represents death or re-transplant as a 
young adult. Clearly CAV remains a great concern for those involved in paediatric 
transplantation.  
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Paediatric patients provide a relatively homogeneous population to study CAV. The 
confounding effects of other risk factors for transplant coronary disease, such as 
diabetes, hypertension, smoking and elderly donors, are minimized.
203
 Furthermore, 
there is acceleration of vascular disease post-transplant from a relatively low 
background level, which is quantifiable with the sensitive technique of intravascular 
ultrasound. The previous demonstration at Great Ormond Street of a link between CMV 
and graft vasculopathy used only angiography.
174
 It is important that detailed IVUS 
investigation (using measurement of intimal-media percentage area for the first time in a 
paediatric series) has confirmed this hypothesis.  
 
The current methodology differs somewhat from the few substantive paediatric IVUS 
papers and assessments of CMV in transplantation.
196, 197
 This study used a 
measurement of intima/media percentage area to represent the severity of diffuse 
transplant coronary disease. Furthermore, I have chosen not to include patients with 
positive viral cultures or CMV DNA by PCR in the blood at the time of the study, as 
acute infection can alter peripheral vascular testing.
181
 Instead, I assessed chronic 
subclinical CMV replication by dividing our population by CMV IgG status. I believe it 
is the chronic exposure to CMV which is key to vascular disease. Indeed, protection 
against subclinical CMV replication via T-cell immunity has been shown to reduce 
CAV,
188
 as has anti-CMV prophylaxis,
186
 and the prevention of vasculopathy by 
everolimus has been linked to its anti-CMV effects.
205
  
 
In addition to the morphological changes seen in the coronary arteries, this chapter has 
also demonstrated a similar thickening of the carotid arteries of CMV-positive 
transplanted children. Carotid IMT is known to be an indicator of systemic 
atherosclerosis and coronary artery disease in non-transplant patients,
206, 207
 and has 
been used previously to demonstrate an atherosclerotic tendency in paediatric transplant 
recipients,
208
 but this is the first time that CMV has been implicated. This 
morphological change is reflected in the functional impairment demonstrated by the 
contemporaneous brachial artery FMD results. 
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There is obvious overlap between the FMD investigations of this and the previous 
chapter. In Chapter 7, analysis by CMV IgG alone showed a trend towards worse FMD 
for IgG positive patients, but this failed to reach clinical significance. I hypothesised 
there that that study was not sufficiently sensitive to illustrate a statistical difference on 
IgG alone, and post-transplant replication acted as a filter to select those patients that 
would have a more severe vascular phenotype. In this chapter, with the patients being 
more closely matched, it appears that CMV IgG positivity alone is enough to 
demonstrate that difference. 
 
Although systemic impairment is likely to be less important clinically to this group of 
patients than coronary changes, the relevance of damage to native arteries should not be 
ignored. Firstly, the ability of CMV to cause vascular injury without additional donor-
host immune interactions is important in understanding the pathogenesis of viral-
mediated vascular damage post-transplant. It also leads to speculation that similar 
damage may be occurring in non-transplant immunosuppressed states. Furthermore, 
non-invasive investigations of systemic arteries may potentially identify a group of low 
vasculopathy risk patients and decrease the frequency of coronary surveillance required 
to check for CAV. With one of the goals of transplant programmes being a resumption 
of as normal a lifestyle as possible, this would be of obvious benefit. 
 
The control group had an expected incidence of CMV seroconversion,
209
 and age-
matched the transplantation group well; the increase in CMV-positivity in the 
transplantation group was due to the typical increase in seroconversion post-transplant. I 
found no difference in measures of arterial structure and function in the systemic 
arteries of the control group, suggesting that in CMV-positive immunocompetent 
children, viral activity is insufficient to produce such accelerated injury. Direct 
comparison of transplanted and healthy children is debatable, but it is interesting that 
CMV IgG-negative transplant recipients have values for brachial FMD and cIMT that 
are similar to non-transplant controls. One interpretation of these results is that – 
without the added insult of CMV replication – transplanted children do not suffer 
systemic vascular injury. 
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These results confirm the need to target CMV replication post-transplantation. What 
remains in doubt is the optimal approach for combating the effects of CMV in solid 
organ transplantation. With no vaccine currently available, therapeutic strategies are 
split between pre-emptive and prophylactic options.
210
 The possibility of indefinite anti-
viral therapy has been explored in lung transplantation.
211
 However, current therapies 
are expensive and potentially harmful. 
 
I was unable to randomise the transplant patients with respect to CMV, for obvious 
reasons. The cross-sectional nature of this paper also limits insight into how the 
vascular health of these patients will be affected in the long-term by CMV. However, 
these findings are strengthened by the fact that paediatric transplant patients are a 
relatively homogeneous group less confounded by the risk factors for coronary disease 
seen in adult patients, and using a single centre experience further limited the potential 
for bias. 
8.4 CONCLUSIONS 
These findings emphasize the importance of CMV infection in paediatric heart 
transplantation. The earlier angiographic and physiological data has been extended 
through the application of accurate quantitative analysis using extracorporeal and 
intravascular ultrasound. This chapter has implicated subclinical CMV replication in 
coronary artery vasculopathy and, beyond the donor organ-recipient interaction, in 
systemic vascular changes and endothelial dysfunction. Each of these findings could 
prove detrimental to long-term outcome. Normal children, however, showed no 
systemic changes after CMV IgG seroconversion, implying the increase in 
vasculopathic CMV activity is a phenomenon of the immunosuppressed state. 
 CHAPTER 9 
CONCLUSIONS AND POTENTIAL                                         
FUTURE DIRECTIONS 
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9.1 OVERVIEW 
My aim when setting out on this body of work was to look at various aspects of the 
heart transplant journey for children, to understand better the factors that control success 
of the procedure. A successful heart transplant programme is the result of the 
culmination myriad components, each of which effects the patient directly, and – 
through interactions with other components – more indirectly, the product of which, we 
hope, is a healthy graft that lasts for as long as possible. Through dedicated research and 
clinical teams throughout the history of transplant medicine, these components have 
been studied, understood and improved, and have facilitated the successful care with 
which we provide our patients today. 
 
The study of the entirety of paediatric heart transplantation would be beyond the scope 
of a single thesis. For this reason, I selected specific areas within the transplant sphere 
with which the Heart Transplant Team at Great Ormond Street had particular issues. I 
designed the project with a broad aim in mind – to look at children at various stages of 
their transplant life (namely pre-transplant, peri-transplant and post-transplant), to 
appreciate areas where changes have enhanced the outlook for these patients, and 
recognise factors that require further study and improvements. It was crucial, however, 
that this broad aim was broken down into specific, discrete and answerable questions.  
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The focus of Chapter 3 was the effect of pre-transplant diagnosis on post-transplant 
outcomes. It was designed to challenge the accepted teaching that patients with 
congenital heart disease had worse outcomes than those transplanted for 
cardiomyopathy. This teaching had several potential justifications: patients with 
congenital heart disease were more likely to have had previous operations, associated 
anatomical abnormalities (particularly vascular), and multi-organ dysfunction than their 
cardiomyopathic counterparts. However, the team at Great Ormond Street had felt that 
in the most recent era, our results for transplantation for congenital heart disease had 
greatly improved. The hypothesis of the work, therefore, was that the difference in 
outcomes for these two groups was largely due to a relatively high early attrition seen in 
the immediate post-operative period in congenital patients, which could be overcome 
with increasing experience in operating on this heterogeneous group. (Experience in the 
more homogeneous cardiomyopathy group was gained quickly by many centres around 
the globe). For this theory to stand up, I had to show that although historically 
transplantation for congenital heart disease had worse outcomes than for 
cardiomyopathy, the discrepancy had disappeared in the recent era. Since the crucial 
factor here was increasing surgical and intensive care experience, rather than a specific 
improvement (an evolution, rather than a revolution) an arbitrary time point of the 
Millennium was chosen to divide the programme into two approximately equal parts. 
Chapter 3 does indeed indicate that results of transplantation for congenital heart disease 
are now – at our institution – equal to those for cardiomyopathy, a result which is not 
yet echoed throughout the world of heart transplantation. I attribute the relative success 
in these patients of the Great Ormond Street heart transplant unit to the willingness to 
take on these difficult patients, the result of which has been the elusive but crucial 
experience in performing transplantation in this setting.  
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Chapter 4 moved chronologically onwards in the transplant journey, to assess the 
impact of peri-operative induction immunosuppression in our patients. The specific 
issue here was to review the success of the change in policy to administer basiliximab 
prior to cardio-pulmonary bypass. The basis of this decision was that – as a monoclonal 
antibody – concerns over washout during bypass of the effect of basiliximab were 
unfounded, and that perhaps added protection in the immediate post-operative phase 
might be beneficial (when the potential for immunological stimulation and damage 
might be considered highest). This work showed that post-operative administration of 
basiliximab in our patients had had no protective effect against early rejection when 
compared to no induction or anti-thymocyte globulin, but that pre-bypass delivery 
reduced post-transplant rejection and early mortality, thereby justifying the change in 
clinical protocol. 
 
The purpose of Chapter 5 was to examine the reasons and risk factors associated with 
the need for extra-corporeal life support in the early post-operative period. Although 
increasing surgical and intensive care expertise has greatly reduced early mortality 
following heart transplantation, a significant proportion of patients still require 
mechanical support to bridge them through this challenging time. My work highlighted 
the relatively frequent need for ECLS (compared to conventional cardiac surgery), but 
illustrated the excellent medium-term survival for the patients who survived to hospital 
discharge, supporting its use. Importantly, I was able to identify restrictive 
cardiomyopathy, longer ischaemic times and extreme donor:recipient weight mismatch 
as risk factors for the need for ECLS. These factors are now used to guide our peri-
operative care, particularly the use of nitric oxide and other pulmonary vasodilators, as 
well as the creation of an inter-atrial communication during surgery. 
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Whereas much of the development of heart transplantation has been directed at 
improvements in early mortality, the final section of my thesis was designed to focus on 
the long-term health (both cardiac and non-cardiac) of our patients. This is especially 
important for paediatric heart transplant recipients, whose grafts can only be expected to 
survive for around twenty years. The preservation of the graft is therefore paramount, 
along with the avoidance of other organ damage, which would preclude them from re-
transplantation in the future. Chapter 6 looked at the side effect profile of tacrolimus, 
noting reductions in renal impairment and hypertension in patients following a switch 
from ciclosporin. The overall incidence of serious chronic side-effects in the study 
population was low, which may be also attributable to the early weaning of 
prednisolone in the majority of patients. 
 
Chapters 7 and 8 examined the effects of cytomegalovirus on vascular health in 
transplant patients. Chapter 7 concluded that systemic vascular health in transplant 
recipients who had exhibited post-transplant CMV replication to be significantly 
impaired compared to those who had not. This laid the foundation for the additional 
study in Chapter 8 probing those effects further. By measuring intimal thickness 
measurements with intravascular ultrasound, for the first time in paediatric patients it 
was possible to link CMV with quantifiable coronary vascular damage post-heart 
transplant. I also looked at the systemic arteries of non-transplant children. This healthy, 
immunocompetent group exhibited no such discrepancy in vascular health based on 
CMV status, confirming the changes seen in the transplant population had occurred 
post-operatively. Since these studies have concluded, the transplant team at Great 
Ormond Street have moved towards earlier treatment of CMV replication, in an attempt 
to limit the effects of CMV post-transplant.  
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9.2 FUTURE WORK 
Of course, there are important components of the transplant journey that were not the 
primary considerations of this thesis. Pre-transplant health, mechanical bridging to 
transplantation, organ harvesting and preservation, operative technique and re-
transplantation are only some of the areas where further study is required. The 
following, however, are suggestions for possible future study that leads on from my 
work directly. 
9.2.1 Mechanical rescue therapies for early graft failure 
This thesis has outlined some of the risk factors for early graft failure and need for 
ECLS post-transplant. Although long-term outlook for those surviving to hospital 
discharge is excellent, there remain unsolved problems around this field. The proportion 
of patients needing ECLS is much higher in transplant than in conventional cardiac 
surgery – and predictably so. Protective steps, such as pulmonary vasodilatation and 
interatrial communications have certainly helped, but with such a significant mortality 
and morbidity burden associated with ELCS, further prevention is required. Perhaps 
earlier pre-transplant mechanical support, particularly in the case of a failing (or even 
potentially failing) right heart, might result in a reduction in mortality. With increasing 
expertise – not just in paediatric ECMO, but also paediatric ventricular assist devices – 
future studies may be able to demonstrate additional survival benefit in this challenging 
sub-group of patients. 
 
One important study might look at the reversibility of high PVR whilst waiting for 
transplant on medical therapy (such as milrinone) compared to mechanical support. 
With more and more patients remaining as inpatients for three months or more, the 
results of PVR testing in the catheter laboratory at the point of listing and 3 months later 
could be compared, and any reduction further compared to improvements in immediate 
and long-term post-transplant outcome. It may also be possible to take direct 
measurements on the operating table prior to the commencement of cardiopulmonary 
bypass at the time of transplant, to define more accurately any improvements in 
pulmonary vascular physiology. 
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9.2.2 Immunosuppression in paediatric heart transplantation 
Until the holy grails of either immune tolerance to transplanted grafts, or even 
implantation of non-immune organs are found, immunosuppression will continue as the 
double-edged sword of transplant medicine. Unfortunately, not only do today‘s agents 
have unwanted side-effects (e.g. hypertension, renal impairment), but their 
immunosuppressive effects leave the transplant recipient vulnerable to infection and 
post-transplant malignancy. In addition, under-immunosuppression brings with it 
potentially devastating rejection. Chapters 4 and 6 examined the use of 
immunosuppressive drugs in paediatric heart transplantation, but these studies, as well 
as current clinical practice, are limited by the inability to closely and accurately monitor 
immune function in our patients. Rather, we rely on crude surrogate markers (e.g. levels 
of drug metabolites) to direct immunosuppressant use. A possible solution to this would 
be the development of cost-effective, quick, reliable assays of immune function that 
would facilitate the highest protection against rejection with the lowest side-effect 
profile.  
 
One potential study would be to compare the results of such an assay to the traditional 
method of trough tacrolimus level in being able to predict rejection. If results were 
encouraging, a cross-over trial of immune assay vs. tacrolimus levels in preventing 
rejection in new transplant recipients (using their clinically indicated one, three and six-
month biopsies as outcome measures). 
9.2.3 Cytomegalovirus and heart transplantation 
The final two chapters of this thesis linked CMV with vascular impairment post-
transplant, in particular with cardiac allograft vasculopathy, which remains the most 
important factor limiting long-term success in heart transplantation. However, it 
remains unclear why some patients with CMV remain relatively free of coronary 
problems, whilst others succumb to rapidly progressive, severe disease. One crucial 
unsolved riddle is the mechanism by which CMV causes these changes. My work has 
been fundamental to the development of an on-going study at Great Ormond Street 
probing the mechanism of CMV in transplant vasculopathy, looking at the number and 
function of various parts of the immune system, including T-lymphocytes, smooth 
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muscle cells, and circulating endothelial cells, in order to understand whether it is the 
virus itself, or the innate immune response to the virus, that is driving the vascular 
changes. Understanding this will be pivotal in developing management strategies, 
potentially prior to transplantation and certainly post-transplantation, to limit the effects 
of this common virus. 
 
Once the results of these cellular studies are known, applying them to clinical practise 
through translational research will be crucial. The next stage might involve 
investigating the effects of anti-viral medication (e.g. ganciclovir) or even a CMV 
vaccine in controlling the cellular and molecular changes seen in patients who CMV 
levels have risen, and, of course, comparing to clinical CMV outcomes, including the 
systemic and coronary vascular changes investigated in Chapters 7 and 8.  
9.3 CONCLUSION 
Paediatric heart transplantation remains the only long-term solution for end-stage heart 
failure in children. Although the principles of operative technique, intensive care 
management and immunosuppression have been largely standardised, there remain 
significant unanswered questions in transplant medicine, and this thesis has attempted to 
investigate some of these.  
 
Already, the research presented here has proved useful, both at Great Ormond Street 
and at other units, by challenging accepted teaching, justifying current practices, and 
changing others. In addition, it forms the basis for current on-going work, and I hope it 
will lay the foundation for other studies in the future. It is only through persistent 
investigation that we can hope to provide our patients with the best possible outlook in 
this challenging field. 
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